

WEBVTT

NOTE duration:"01:00:02.4110000"

NOTE language:en-us

NOTE Confidence: 0.8628772

00:00:00.000 --> 00:00:02.285 Welcome again to Cancer Center.

NOTE Confidence: 0.8628772

00:00:02.285 --> 00:00:04.094 Grand rounds, good afternoon

NOTE Confidence: 0.8628772

00:00:04.094 --> 00:00:06.776 and as is often the case,

NOTE Confidence: 0.8628772

00:00:06.780 --> 00:00:09.916 is always the case in our forum.

NOTE Confidence: 0.8628772

00:00:09.920 --> 00:00:13.273 We have some really exciting data and

NOTE Confidence: 0.8628772

00:00:13.273 --> 00:00:15.601 progress and science and clinical

NOTE Confidence: 0.8628772

00:00:15.601 --> 00:00:18.422 care to share with you in this.

NOTE Confidence: 0.8628772

00:00:18.430 --> 00:00:20.026 The theme for today,

NOTE Confidence: 0.8628772

00:00:20.026 --> 00:00:23.000 which is a really interesting one and

NOTE Confidence: 0.8628772

00:00:23.000 --> 00:00:26.036 different because we have multiple speakers,

NOTE Confidence: 0.8628772

00:00:26.040 --> 00:00:28.728 is in hematology where we've made,

NOTE Confidence: 0.8628772

00:00:28.730 --> 00:00:30.894 I think, enormous progress.

NOTE Confidence: 0.8628772

00:00:30.894 --> 00:00:34.140 And we're both biology translational work,

NOTE Confidence: 0.8628772

00:00:34.140 --> 00:00:37.236 population science and clinical care in

NOTE Confidence: 0.8628772

00:00:37.236 --> 00:00:40.532 the major hematologic latency is leukemia

NOTE Confidence: 0.8628772

00:00:40.532 --> 00:00:42.828 and myeloid malignancy's lymphoma.

NOTE Confidence: 0.8628772

00:00:42.830 --> 00:00:46.379 Multiple myeloma where I think we have

NOTE Confidence: 0.8628772

00:00:46.379 --> 00:00:49.726 really talented people working on these

NOTE Confidence: 0.8628772

00:00:49.726 --> 00:00:52.631 problems and really translating science

NOTE Confidence: 0.8628772

00:00:52.631 --> 00:00:55.976 into progress for our patients and

NOTE Confidence: 0.8628772

00:00:55.976 --> 00:00:59.114 looking forward to all four presentations.

NOTE Confidence: 0.8628772

00:00:59.120 --> 00:01:03.544 But I I will actually turn to our.

NOTE Confidence: 0.8628772

00:01:03.550 --> 00:01:05.968 Essentially, our leader and host for

NOTE Confidence: 0.8628772

00:01:05.968 --> 00:01:08.950 the session to make the introductions,

NOTE Confidence: 0.8628772

00:01:08.950 --> 00:01:11.650 so I'll start simply by introducing

NOTE Confidence: 0.8628772

00:01:11.650 --> 00:01:13.000 Doctor Stephanie Allyne.

NOTE Confidence: 0.8628772

00:01:13.000 --> 00:01:14.329 As you know,

NOTE Confidence: 0.8628772

00:01:14.329 --> 00:01:17.950 Stephanie is the chief of hematology at Yale,

NOTE Confidence: 0.8628772

00:01:17.950 --> 00:01:20.200 as well as an associate

NOTE Confidence: 0.8628772

00:01:20.200 --> 00:01:21.550 professor of medicine.
NOTE Confidence: 0.8628772

00:01:21.550 --> 00:01:22.374 In addition,
NOTE Confidence: 0.8628772

00:01:22.374 --> 00:01:24.434 Stephanie Overseas the DeLuca Center
NOTE Confidence: 0.8628772

00:01:24.434 --> 00:01:26.949 for Innovation and Hematology Research,
NOTE Confidence: 0.8628772

00:01:26.950 --> 00:01:28.950 which is really an exciting
NOTE Confidence: 0.8628772

00:01:28.950 --> 00:01:31.900 addition to our work in hematology,
NOTE Confidence: 0.8628772

00:01:31.900 --> 00:01:34.498 with the promise that not only
NOTE Confidence: 0.8628772

00:01:34.498 --> 00:01:35.797 translating our discoveries
NOTE Confidence: 0.8628772

00:01:35.797 --> 00:01:38.030 into clinical care innovation.
NOTE Confidence: 0.8628772

00:01:38.030 --> 00:01:41.144 But also in furthering the support
NOTE Confidence: 0.8628772

00:01:41.144 --> 00:01:44.200 of our faculty and trainees.
NOTE Confidence: 0.8628772

00:01:44.200 --> 00:01:47.528 Stephanie joined the faculty in Yale in 2006.
NOTE Confidence: 0.8628772

00:01:47.530 --> 00:01:50.738 An we were so pleased that she was
NOTE Confidence: 0.8628772

00:01:50.738 --> 00:01:53.462 selected as our new Chief in 2020
NOTE Confidence: 0.8628772

00:01:53.462 --> 00:01:56.771 and is doing a great job and looking
NOTE Confidence: 0.8628772

00:01:56.771 --> 00:01:59.543 forward to her an our faculty

NOTE Confidence: 0.8628772

00:01:59.543 --> 00:02:02.090 sharing the exciting work at Yale.

NOTE Confidence: 0.8628772

00:02:02.090 --> 00:02:04.580 So Stephanie I turn to you.

NOTE Confidence: 0.6479419

00:02:06.650 --> 00:02:08.140 Let me share my slides.

NOTE Confidence: 0.87615436

00:02:11.490 --> 00:02:13.940 OK, can you see the slides well?

NOTE Confidence: 0.87615436

00:02:13.940 --> 00:02:14.855 Yes, OK, Alright,

NOTE Confidence: 0.87615436

00:02:14.855 --> 00:02:16.380 let's tally Saturday will preside,

NOTE Confidence: 0.87615436

00:02:16.380 --> 00:02:17.905 present or represent on translational

NOTE Confidence: 0.87615436

00:02:17.905 --> 00:02:18.820 science and hematology.

NOTE Confidence: 0.87615436

00:02:18.820 --> 00:02:20.955 And there will be four of us,

NOTE Confidence: 0.87615436

00:02:20.960 --> 00:02:23.696 so I will be the one driving the slide.

NOTE Confidence: 0.87615436

00:02:23.700 --> 00:02:25.960 So any hiccups blame me.

NOTE Confidence: 0.87615436

00:02:25.960 --> 00:02:27.316 Um, so I'll be.

NOTE Confidence: 0.87615436

00:02:27.316 --> 00:02:29.350 I'll be giving a brief introduction

NOTE Confidence: 0.87615436

00:02:29.417 --> 00:02:31.507 to hematology and then tomorrow

NOTE Confidence: 0.87615436

00:02:31.507 --> 00:02:33.597 probably will present on behalf

NOTE Confidence: 0.87615436

00:02:33.671 --> 00:02:36.161 of the myeloid malignancies team
NOTE Confidence: 0.87615436

00:02:36.161 --> 00:02:37.655 and traumatizing associate,
NOTE Confidence: 0.87615436

00:02:37.660 --> 00:02:38.974 professor of medicine,
NOTE Confidence: 0.87615436

00:02:38.974 --> 00:02:39.412 hematology,
NOTE Confidence: 0.87615436

00:02:39.412 --> 00:02:42.511 and he's a director of the MLP
NOTE Confidence: 0.87615436

00:02:42.511 --> 00:02:44.091 malignancies disease team and
NOTE Confidence: 0.87615436

00:02:44.091 --> 00:02:46.859 the firm chief of the data firm,
NOTE Confidence: 0.87615436

00:02:46.860 --> 00:02:49.050 and everybody knows just how
NOTE Confidence: 0.87615436

00:02:49.050 --> 00:02:51.702 much moving Anan changes had to
NOTE Confidence: 0.87615436

00:02:51.702 --> 00:02:54.006 happen over the past years to
NOTE Confidence: 0.87615436

00:02:54.006 --> 00:02:56.389 keep our clinical services alive.
NOTE Confidence: 0.87615436

00:02:56.390 --> 00:02:58.754 And to my actually completed his
NOTE Confidence: 0.87615436

00:02:58.754 --> 00:03:01.840 doctor rent in medical hematology oncology.
NOTE Confidence: 0.87615436

00:03:01.840 --> 00:03:04.150 Myung then joined the Paoli
NOTE Confidence: 0.87615436

00:03:04.150 --> 00:03:05.998 Calmettes's Institute in Marseille
NOTE Confidence: 0.87615436

00:03:05.998 --> 00:03:08.715 and did a full ride scholarship

NOTE Confidence: 0.87615436

00:03:08.715 --> 00:03:10.459 at Johns Hopkins University,

NOTE Confidence: 0.87615436

00:03:10.460 --> 00:03:13.184 and I think that's how eventually

NOTE Confidence: 0.87615436

00:03:13.184 --> 00:03:15.000 he landed with us.

NOTE Confidence: 0.87615436

00:03:15.000 --> 00:03:17.270 With Steve Gore recruiting him.

NOTE Confidence: 0.87615436

00:03:17.270 --> 00:03:19.540 After tomorrow, Doctor Francine Foss,

NOTE Confidence: 0.87615436

00:03:19.540 --> 00:03:21.356 Professor of Medicine and

NOTE Confidence: 0.87615436

00:03:21.356 --> 00:03:22.718 hematology and Rheumatology,

NOTE Confidence: 0.87615436

00:03:22.720 --> 00:03:24.648 would present on behalf

NOTE Confidence: 0.87615436

00:03:24.648 --> 00:03:27.058 of the former team and.

NOTE Confidence: 0.87615436

00:03:27.060 --> 00:03:29.310 Francine really is the expert in

NOTE Confidence: 0.87615436

00:03:29.310 --> 00:03:30.821 T cell lymphoma, internationally,

NOTE Confidence: 0.87615436

00:03:30.821 --> 00:03:31.583 nationally, renown,

NOTE Confidence: 0.87615436

00:03:31.583 --> 00:03:34.250 and she's a research director of an

NOTE Confidence: 0.87615436

00:03:34.310 --> 00:03:36.085 informal disease team and obviously

NOTE Confidence: 0.87615436

00:03:36.085 --> 00:03:38.340 director of the Tucson Informer program,

NOTE Confidence: 0.87615436

00:03:38.340 --> 00:03:40.572 and you will hear exciting news
NOTE Confidence: 0.87615436

00:03:40.572 --> 00:03:43.252 what is happening in the format to
NOTE Confidence: 0.87615436

00:03:43.252 --> 00:03:45.856 selling Thelma and last but not least,
NOTE Confidence: 0.87615436

00:03:45.860 --> 00:03:46.886 doesn't Italian infrared,
NOTE Confidence: 0.87615436

00:03:46.886 --> 00:03:49.280 so will present on behalf of the
NOTE Confidence: 0.87615436

00:03:49.347 --> 00:03:51.119 multiple myeloma disease team.
NOTE Confidence: 0.87615436

00:03:51.120 --> 00:03:53.135 And she's the research director
NOTE Confidence: 0.87615436

00:03:53.135 --> 00:03:55.648 of the much more disease team
NOTE Confidence: 0.87615436

00:03:55.648 --> 00:03:57.748 and an assistant professor in.
NOTE Confidence: 0.87615436

00:03:57.750 --> 00:03:58.908 Medicine medical oncology.
NOTE Confidence: 0.87615436

00:03:58.908 --> 00:04:01.224 She actually obtained her medical degree
NOTE Confidence: 0.87615436

00:04:01.224 --> 00:04:03.715 in Tennessee and the country of Georgia,
NOTE Confidence: 0.87615436

00:04:03.720 --> 00:04:06.228 then did postdoctoral fellowships at Emory
NOTE Confidence: 0.87615436

00:04:06.228 --> 00:04:08.570 Northwestern and Lucky for us a deal.
NOTE Confidence: 0.87615436

00:04:08.570 --> 00:04:10.808 She did her residency and fellowship.
NOTE Confidence: 0.87615436

00:04:10.810 --> 00:04:12.670 Odiele refill Oscar left us,

NOTE Confidence: 0.87615436

00:04:12.670 --> 00:04:15.631 but we were able to recruit her

NOTE Confidence: 0.87615436

00:04:15.631 --> 00:04:18.718 back to be part of the team.

NOTE Confidence: 0.87615436

00:04:18.720 --> 00:04:19.464 So um,

NOTE Confidence: 0.87615436

00:04:19.464 --> 00:04:21.696 before I introduce much about hematology,

NOTE Confidence: 0.87615436

00:04:21.700 --> 00:04:23.890 I think it's absolutely time that

NOTE Confidence: 0.87615436

00:04:23.890 --> 00:04:26.530 we all say thank you to Charlie.

NOTE Confidence: 0.87615436

00:04:26.530 --> 00:04:27.286 So Charlie,

NOTE Confidence: 0.87615436

00:04:27.286 --> 00:04:29.554 you took over as our interim

NOTE Confidence: 0.87615436

00:04:29.554 --> 00:04:31.451 section Chief in January 2018

NOTE Confidence: 0.87615436

00:04:31.451 --> 00:04:33.593 and has been a just wonderful,

NOTE Confidence: 0.87615436

00:04:33.600 --> 00:04:35.064 wonderful journey since then.

NOTE Confidence: 0.87615436

00:04:35.064 --> 00:04:38.072 So you can see just how big the

NOTE Confidence: 0.87615436

00:04:38.072 --> 00:04:40.298 group is in hematology and growing.

NOTE Confidence: 0.87615436

00:04:40.300 --> 00:04:43.092 And I just want to read a few

NOTE Confidence: 0.87615436

00:04:43.092 --> 00:04:46.219 of the quotes from our faculty.

NOTE Confidence: 0.87615436

00:04:46.220 --> 00:04:48.180 And that is so Charlie,
NOTE Confidence: 0.87615436

00:04:48.180 --> 00:04:49.660 you recognize the strength,
NOTE Confidence: 0.87615436

00:04:49.660 --> 00:04:51.140 resilience and enthusiasm in
NOTE Confidence: 0.87615436

00:04:51.140 --> 00:04:53.260 the new teologi faculty, staff,
NOTE Confidence: 0.87615436

00:04:53.260 --> 00:04:54.430 advanced practice providers,
NOTE Confidence: 0.87615436

00:04:54.430 --> 00:04:55.600 nurses entry needs,
NOTE Confidence: 0.87615436

00:04:55.600 --> 00:04:59.119 and you supported our teams in so many ways.
NOTE Confidence: 0.87615436

00:04:59.120 --> 00:05:01.364 Thank you for the leadership and
NOTE Confidence: 0.87615436

00:05:01.364 --> 00:05:03.819 commitment you provided as interim Chief.
NOTE Confidence: 0.87615436

00:05:03.820 --> 00:05:05.930 Your strong support and advocacy
NOTE Confidence: 0.87615436

00:05:05.930 --> 00:05:09.040 for our section is not appreciated.
NOTE Confidence: 0.87615436

00:05:09.040 --> 00:05:10.720 Thank you for being an outstanding
NOTE Confidence: 0.87615436

00:05:10.720 --> 00:05:12.560 leader and role model for trainees
NOTE Confidence: 0.87615436

00:05:12.560 --> 00:05:13.900 through your dedication to
NOTE Confidence: 0.87615436

00:05:13.900 --> 00:05:15.240 excellence in patient care,
NOTE Confidence: 0.87615436

00:05:15.240 --> 00:05:16.140 teaching and innovation.

NOTE Confidence: 0.87615436

00:05:16.140 --> 00:05:18.620 It has been an honor to learn from

NOTE Confidence: 0.87615436

00:05:18.620 --> 00:05:20.510 you and the excellent faculty of

NOTE Confidence: 0.87615436

00:05:20.510 --> 00:05:22.384 your Cancer Center and thank you

NOTE Confidence: 0.87615436

00:05:22.384 --> 00:05:24.286 for everything you've done for the

NOTE Confidence: 0.87615436

00:05:24.286 --> 00:05:26.423 Cancer Center and was a section of

NOTE Confidence: 0.87615436

00:05:26.423 --> 00:05:27.868 hematology over the past several

NOTE Confidence: 0.85808015

00:05:27.932 --> 00:05:29.994 years. You have been a wonderful resource

NOTE Confidence: 0.85808015

00:05:29.994 --> 00:05:32.289 and a guide from my academic growth,

NOTE Confidence: 0.85808015

00:05:32.290 --> 00:05:34.150 and I'm extremely grateful to you.

NOTE Confidence: 0.85808015

00:05:34.150 --> 00:05:35.390 So thank you, Charlie.

NOTE Confidence: 0.82367754

00:05:36.770 --> 00:05:39.160 Thank you in the entire division.

NOTE Confidence: 0.82367754

00:05:39.160 --> 00:05:41.905 It's a real point of pride to me

NOTE Confidence: 0.82367754

00:05:41.905 --> 00:05:44.932 to have been a member and now and

NOTE Confidence: 0.82367754

00:05:44.932 --> 00:05:47.534 along of this very August center

NOTE Confidence: 0.82367754

00:05:47.534 --> 00:05:49.898 of excellence. So thank you.

NOTE Confidence: 0.7637411

00:05:51.780 --> 00:05:54.858 And we have a little bit more in store,
NOTE Confidence: 0.7637411

00:05:54.860 --> 00:05:57.180 so the thing we really wanted to thank
NOTE Confidence: 0.7637411

00:05:57.180 --> 00:05:59.955 you for is how you have supported all
NOTE Confidence: 0.7637411

00:05:59.955 --> 00:06:02.193 our people and recruitment of all
NOTE Confidence: 0.7637411

00:06:02.193 --> 00:06:04.088 these people highlighted in yellow.
NOTE Confidence: 0.7637411

00:06:04.090 --> 00:06:06.043 You know Murrayshall is to my like
NOTE Confidence: 0.7637411

00:06:06.043 --> 00:06:08.542 my name is this team chilling costar
NOTE Confidence: 0.7637411

00:06:08.542 --> 00:06:10.930 Intercine safely to the lymphoma team.
NOTE Confidence: 0.7637411

00:06:10.930 --> 00:06:12.982 Barbona is our director of classic
NOTE Confidence: 0.7637411

00:06:12.982 --> 00:06:15.210 hematology, Sabrina Browning as a member
NOTE Confidence: 0.7637411

00:06:15.210 --> 00:06:18.108 of our myeloma and come up as a team.
NOTE Confidence: 0.7637411

00:06:18.110 --> 00:06:19.820 And as you can see,
NOTE Confidence: 0.7637411

00:06:19.820 --> 00:06:22.180 also of our billing team.
NOTE Confidence: 0.7637411

00:06:22.180 --> 00:06:24.238 And then in addition to that,
NOTE Confidence: 0.7637411

00:06:24.240 --> 00:06:25.592 you have recruited hematology
NOTE Confidence: 0.7637411

00:06:25.592 --> 00:06:28.028 focused faculty to the to the Smiler

NOTE Confidence: 0.7637411

00:06:28.028 --> 00:06:29.748 network and the care centers,

NOTE Confidence: 0.7637411

00:06:29.750 --> 00:06:31.814 and we're so fortunate to work

NOTE Confidence: 0.7637411

00:06:31.814 --> 00:06:33.190 with all our colleagues.

NOTE Confidence: 0.7637411

00:06:33.190 --> 00:06:35.598 And of course Mike's mission as a director

NOTE Confidence: 0.7637411

00:06:35.598 --> 00:06:38.346 of the Center for Molecular and Cellular.

NOTE Confidence: 0.7637411

00:06:38.350 --> 00:06:40.276 I always say hematology and oncology

NOTE Confidence: 0.7637411

00:06:40.276 --> 00:06:42.480 in there were so excited about,

NOTE Confidence: 0.7637411

00:06:42.480 --> 00:06:45.488 you know, all our new people and teams

NOTE Confidence: 0.7637411

00:06:45.488 --> 00:06:48.247 and what we can achieve together.

NOTE Confidence: 0.7637411

00:06:48.250 --> 00:06:48.916 So, um,

NOTE Confidence: 0.7637411

00:06:48.916 --> 00:06:51.247 so now in my introduction to hematology.

NOTE Confidence: 0.7637411

00:06:51.250 --> 00:06:54.238 So what you see here is kind of our.

NOTE Confidence: 0.7637411

00:06:54.240 --> 00:06:55.910 These are hematology core teams.

NOTE Confidence: 0.7637411

00:06:55.910 --> 00:06:58.276 I say core because these are the

NOTE Confidence: 0.7637411

00:06:58.276 --> 00:07:00.239 people located in in New Haven,

NOTE Confidence: 0.7637411

00:07:00.240 --> 00:07:00.968 North Haven.
NOTE Confidence: 0.7637411

00:07:00.968 --> 00:07:03.516 And these are the teams that are
NOTE Confidence: 0.7637411

00:07:03.516 --> 00:07:06.048 working hard to bring the best patient
NOTE Confidence: 0.7637411

00:07:06.048 --> 00:07:08.439 care to all patients in Connecticut
NOTE Confidence: 0.7637411

00:07:08.439 --> 00:07:10.739 and beyond through their research
NOTE Confidence: 0.7637411

00:07:10.739 --> 00:07:12.876 that clinical care and collaboration
NOTE Confidence: 0.7637411

00:07:12.876 --> 00:07:15.522 was all the teams we have smile.
NOTE Confidence: 0.7637411

00:07:15.530 --> 00:07:17.810 Oh yeah, even health and University.
NOTE Confidence: 0.7637411

00:07:17.810 --> 00:07:20.842 So we have five teams in my life
NOTE Confidence: 0.7637411

00:07:20.842 --> 00:07:22.734 malignancies team, an informer team,
NOTE Confidence: 0.7637411

00:07:22.734 --> 00:07:24.246 the stem cell transplant,
NOTE Confidence: 0.7637411

00:07:24.250 --> 00:07:26.166 and South Therapies team.
NOTE Confidence: 0.7637411

00:07:26.166 --> 00:07:28.561 We call it classical hematology
NOTE Confidence: 0.7637411

00:07:28.561 --> 00:07:30.218 because as we all know.
NOTE Confidence: 0.7637411

00:07:30.220 --> 00:07:32.656 Behind him, disorders are not that denied.
NOTE Confidence: 0.7637411

00:07:32.660 --> 00:07:35.268 Our patients are quite ill and then our

NOTE Confidence: 0.7637411

00:07:35.268 --> 00:07:37.878 minds from my Loma and commodities team.

NOTE Confidence: 0.7637411

00:07:37.880 --> 00:07:39.620 So as I mentioned before,

NOTE Confidence: 0.7637411

00:07:39.620 --> 00:07:40.661 we're not alone.

NOTE Confidence: 0.7637411

00:07:40.661 --> 00:07:42.396 We're not just a small,

NOTE Confidence: 0.7637411

00:07:42.400 --> 00:07:45.523 tiny little point on the map in New Haven,

NOTE Confidence: 0.7637411

00:07:45.530 --> 00:07:47.756 but through our smaller network we

NOTE Confidence: 0.7637411

00:07:47.756 --> 00:07:49.949 have reached across the entire state

NOTE Confidence: 0.7637411

00:07:49.949 --> 00:07:52.509 and it is just wonderful to know that

NOTE Confidence: 0.7637411

00:07:52.575 --> 00:07:54.948 we can bring the excellent signs and

NOTE Confidence: 0.7637411

00:07:54.948 --> 00:07:57.014 treatment to all patients in Connecticut.

NOTE Confidence: 0.7637411

00:07:57.014 --> 00:07:57.710 Then again,

NOTE Confidence: 0.7637411

00:07:57.710 --> 00:07:59.102 here I'm highlighting our

NOTE Confidence: 0.7637411

00:07:59.102 --> 00:08:00.146 hematology focused faculty,

NOTE Confidence: 0.7637411

00:08:00.150 --> 00:08:02.754 which is also new over the last.

NOTE Confidence: 0.7637411

00:08:02.760 --> 00:08:06.636 Several years and it's just wonderful.

NOTE Confidence: 0.7637411

00:08:06.640 --> 00:08:09.349 How much team building we can do?
NOTE Confidence: 0.7637411

00:08:09.350 --> 00:08:11.744 There are many discussions already going
NOTE Confidence: 0.7637411

00:08:11.744 --> 00:08:14.137 on between our disease team leaders
NOTE Confidence: 0.7637411

00:08:14.137 --> 00:08:16.699 and faculty and tremble in North Haven,
NOTE Confidence: 0.7637411

00:08:16.700 --> 00:08:19.409 Guilford, Hartford and all the other places.
NOTE Confidence: 0.7637411

00:08:19.410 --> 00:08:21.730 So it's wonderful opportunity.
NOTE Confidence: 0.7637411

00:08:21.730 --> 00:08:22.310 Um,
NOTE Confidence: 0.7637411

00:08:22.310 --> 00:08:24.668 we're not alone and we're not
NOTE Confidence: 0.7637411

00:08:24.668 --> 00:08:26.240 doing this in isolation,
NOTE Confidence: 0.7637411

00:08:26.240 --> 00:08:28.550 so we're fortunate to be at a
NOTE Confidence: 0.7637411

00:08:28.550 --> 00:08:31.030 place like here where there are
NOTE Confidence: 0.7637411

00:08:31.030 --> 00:08:32.914 many different centers there.
NOTE Confidence: 0.7637411

00:08:32.920 --> 00:08:35.182 We have our Decker Jews tallied
NOTE Confidence: 0.7637411

00:08:35.182 --> 00:08:37.250 in the clinical Trials Office.
NOTE Confidence: 0.7637411

00:08:37.250 --> 00:08:37.627 Again,
NOTE Confidence: 0.7637411

00:08:37.627 --> 00:08:39.889 Marcus leading that CMC L Michaels

NOTE Confidence: 0.7637411

00:08:39.889 --> 00:08:41.490 bosenberg leading yell center

NOTE Confidence: 0.7637411

00:08:41.490 --> 00:08:43.138 female oncologix Mark Lemon,

NOTE Confidence: 0.7637411

00:08:43.140 --> 00:08:45.105 leading the year Cancer Biology

NOTE Confidence: 0.7637411

00:08:45.105 --> 00:08:46.284 Institute kinda Neugebauer,

NOTE Confidence: 0.7637411

00:08:46.290 --> 00:08:47.954 leading the Larne Center.

NOTE Confidence: 0.7637411

00:08:47.954 --> 00:08:51.777 And then Diane Krause in the my C Age

NOTE Confidence: 0.7637411

00:08:51.777 --> 00:08:54.689 and then cheers of the different departments.

NOTE Confidence: 0.7637411

00:08:54.690 --> 00:08:55.779 Chengdu for pathology.

NOTE Confidence: 0.7637411

00:08:55.779 --> 00:08:57.231 David charts now Department

NOTE Confidence: 0.7637411

00:08:57.231 --> 00:08:58.320 we know immunobiology.

NOTE Confidence: 0.7818945

00:08:58.320 --> 00:08:59.768 We have collaborators in

NOTE Confidence: 0.7818945

00:08:59.768 --> 00:09:01.216 the stem cell center.

NOTE Confidence: 0.7818945

00:09:01.220 --> 00:09:03.768 We have collaborators in the Copper center.

NOTE Confidence: 0.7818945

00:09:03.770 --> 00:09:05.666 Marcella Nunez Smith just gave a

NOTE Confidence: 0.7818945

00:09:05.666 --> 00:09:08.237 talk to to the leaders this morning

NOTE Confidence: 0.7818945

00:09:08.237 --> 00:09:10.297 and Antonio riders and many,
NOTE Confidence: 0.7818945

00:09:10.300 --> 00:09:12.478 many more that I can't even
NOTE Confidence: 0.7818945

00:09:12.478 --> 00:09:13.930 get on this slide.
NOTE Confidence: 0.84497094

00:09:16.270 --> 00:09:18.988 So, um, I just wanted to give a brief
NOTE Confidence: 0.84497094

00:09:18.988 --> 00:09:21.686 update on the Delucas Center for
NOTE Confidence: 0.84497094

00:09:21.686 --> 00:09:23.546 Innovation and Hematology Research,
NOTE Confidence: 0.84497094

00:09:23.550 --> 00:09:25.710 another amazing initiative that Charlie
NOTE Confidence: 0.84497094

00:09:25.710 --> 00:09:29.079 made happen and we are now we've just
NOTE Confidence: 0.84497094

00:09:29.079 --> 00:09:31.718 riding our progress report for the past
NOTE Confidence: 0.84497094

00:09:31.788 --> 00:09:34.650 two years and just to give you an update.
NOTE Confidence: 0.84497094

00:09:34.650 --> 00:09:37.079 So we have a very active hematology
NOTE Confidence: 0.84497094

00:09:37.079 --> 00:09:39.435 tissue bank with samples from patients
NOTE Confidence: 0.84497094

00:09:39.435 --> 00:09:41.925 with all human to logic disorders.
NOTE Confidence: 0.84497094

00:09:41.930 --> 00:09:45.074 We have over 4000 samples from over 2000.
NOTE Confidence: 0.84497094

00:09:45.080 --> 00:09:48.216 Nations, we have a bone marrows prefer blood.
NOTE Confidence: 0.84497094

00:09:48.220 --> 00:09:50.789 We're working **** ** also collecting lymph

NOTE Confidence: 0.84497094

00:09:50.789 --> 00:09:53.330 node tissue and other tissue biopsies.

NOTE Confidence: 0.84497094

00:09:53.330 --> 00:09:55.508 And we also offer specialized processing

NOTE Confidence: 0.84497094

00:09:55.508 --> 00:09:57.660 for clinical trials in hematology.

NOTE Confidence: 0.84497094

00:09:57.660 --> 00:10:00.120 And this is again a huge.

NOTE Confidence: 0.84497094

00:10:00.120 --> 00:10:02.904 Team effort so you see our core people

NOTE Confidence: 0.84497094

00:10:02.904 --> 00:10:05.619 on the right and Michelle Patel,

NOTE Confidence: 0.84497094

00:10:05.620 --> 00:10:06.416 rounder, Feli,

NOTE Confidence: 0.84497094

00:10:06.416 --> 00:10:08.406 Padma Mamillapalli and our latest

NOTE Confidence: 0.84497094

00:10:08.406 --> 00:10:10.340 recruit Jennifer from donor Hoban.

NOTE Confidence: 0.84497094

00:10:10.340 --> 00:10:11.908 But everybody in hematology

NOTE Confidence: 0.84497094

00:10:11.908 --> 00:10:13.476 is contributing to this.

NOTE Confidence: 0.84497094

00:10:13.480 --> 00:10:16.231 All our aips an MP7 in North

NOTE Confidence: 0.84497094

00:10:16.231 --> 00:10:17.410 Haven at Trumbull.

NOTE Confidence: 0.84497094

00:10:17.410 --> 00:10:20.514 Another care centers and we hope to leverage

NOTE Confidence: 0.84497094

00:10:20.514 --> 00:10:23.278 this tissue bank to better understand

NOTE Confidence: 0.84497094

00:10:23.278 --> 00:10:25.668 these users and offering treatments.
NOTE Confidence: 0.84497094

00:10:25.670 --> 00:10:27.675 We have awarded 9 pilot
NOTE Confidence: 0.84497094

00:10:27.675 --> 00:10:29.279 grants or \$50,000 each.
NOTE Confidence: 0.84497094

00:10:29.280 --> 00:10:31.373 Our goal is to have these being
NOTE Confidence: 0.84497094

00:10:31.373 --> 00:10:33.456 through these be collaborative between
NOTE Confidence: 0.84497094

00:10:33.456 --> 00:10:35.700 collisions and basic scientists.
NOTE Confidence: 0.84497094

00:10:35.700 --> 00:10:37.700 We have one career development
NOTE Confidence: 0.84497094

00:10:37.700 --> 00:10:39.300 award E chaining cathari.
NOTE Confidence: 0.84497094

00:10:39.300 --> 00:10:41.890 These are two year awards and the
NOTE Confidence: 0.84497094

00:10:41.890 --> 00:10:44.520 our base posted for new applicants.
NOTE Confidence: 0.84497094

00:10:44.520 --> 00:10:46.550 We have many many applications
NOTE Confidence: 0.84497094

00:10:46.550 --> 00:10:49.329 publications that I could not list here.
NOTE Confidence: 0.84497094

00:10:49.330 --> 00:10:51.410 We have installed the freezer
NOTE Confidence: 0.84497094

00:10:51.410 --> 00:10:53.490 works by repository database and
NOTE Confidence: 0.84497094

00:10:53.565 --> 00:10:55.845 we're very close to populating it.
NOTE Confidence: 0.84497094

00:10:55.850 --> 00:10:58.196 This data that eventually will allow

NOTE Confidence: 0.84497094

00:10:58.196 --> 00:11:00.190 clinician scientists in a deidentified

NOTE Confidence: 0.84497094

00:11:00.190 --> 00:11:02.745 manner screen what we have in the

NOTE Confidence: 0.84497094

00:11:02.745 --> 00:11:05.173 database so they can come up with ideas

NOTE Confidence: 0.84497094

00:11:05.173 --> 00:11:08.000 and let us know how we can help them.

NOTE Confidence: 0.84497094

00:11:08.000 --> 00:11:10.076 We're providing access to novel technologies.

NOTE Confidence: 0.84497094

00:11:10.080 --> 00:11:11.860 Jennifer Amisha Jazz performed single

NOTE Confidence: 0.84497094

00:11:11.860 --> 00:11:13.640 site DNA sequencing for clinical

NOTE Confidence: 0.84497094

00:11:13.700 --> 00:11:15.280 trial samples for to Maccabean.

NOTE Confidence: 0.84497094

00:11:15.280 --> 00:11:17.836 We have many more ideas and we are also

NOTE Confidence: 0.84497094

00:11:17.836 --> 00:11:20.236 seeking to provide Technical Support for

NOTE Confidence: 0.84497094

00:11:20.236 --> 00:11:23.620 correlative studies and data analysis.

NOTE Confidence: 0.84497094

00:11:23.620 --> 00:11:27.130 So let me now go over to the disease teams,

NOTE Confidence: 0.84497094

00:11:27.130 --> 00:11:29.461 so this these are the members of the stem

NOTE Confidence: 0.84497094

00:11:29.461 --> 00:11:32.039 cell transplantation cellular therapies team,

NOTE Confidence: 0.84497094

00:11:32.040 --> 00:11:34.092 but they will not present today

NOTE Confidence: 0.84497094

00:11:34.092 --> 00:11:36.590 because you should stay tuned and log
NOTE Confidence: 0.84497094

00:11:36.590 --> 00:11:38.708 into the Young Cancer Center grounds.
NOTE Confidence: 0.84497094

00:11:38.710 --> 00:11:41.038 I think it's March 23rd when
NOTE Confidence: 0.84497094

00:11:41.038 --> 00:11:43.645 Doctor Supinder for her with her
NOTE Confidence: 0.84497094

00:11:43.645 --> 00:11:45.589 present on cellular therapies.
NOTE Confidence: 0.84497094

00:11:45.590 --> 00:11:48.019 You will also not here today from
NOTE Confidence: 0.84497094

00:11:48.019 --> 00:11:49.420 our classical hematology team,
NOTE Confidence: 0.84497094

00:11:49.420 --> 00:11:51.075 because Doctor Boner just presented
NOTE Confidence: 0.84497094

00:11:51.075 --> 00:11:53.589 not so long ago in grand rounds.
NOTE Confidence: 0.84497094

00:11:53.590 --> 00:11:55.984 But we're also very hopeful to getting
NOTE Confidence: 0.84497094

00:11:55.984 --> 00:11:59.159 a slot in the summer when we will have,
NOTE Confidence: 0.84497094

00:11:59.160 --> 00:12:00.548 hopefully exciting new recruits
NOTE Confidence: 0.84497094

00:12:00.548 --> 00:12:02.283 to add to the team.
NOTE Confidence: 0.84497094

00:12:02.290 --> 00:12:04.838 And we can take a full grand
NOTE Confidence: 0.84497094

00:12:04.838 --> 00:12:07.630 rounds for our classic hematology.
NOTE Confidence: 0.84497094

00:12:07.630 --> 00:12:10.555 So the team you will be hearing from today.

NOTE Confidence: 0.84497094

00:12:10.560 --> 00:12:12.636 The first one is on myeloid

NOTE Confidence: 0.84497094

00:12:12.636 --> 00:12:14.397 malignancy's team and Doctor Priebe

NOTE Confidence: 0.84497094

00:12:14.397 --> 00:12:16.560 will present on behalf of this group

NOTE Confidence: 0.84497094

00:12:16.560 --> 00:12:19.099 and so now I'm heading over to Doctor

NOTE Confidence: 0.84497094

00:12:19.099 --> 00:12:20.670 Kirby for the first presentation.

NOTE Confidence: 0.7442109

00:12:22.260 --> 00:12:24.766 OK, thank you. Thanks a lot Stephanie,

NOTE Confidence: 0.7442109

00:12:24.770 --> 00:12:26.570 for this really kind introduction.

NOTE Confidence: 0.7442109

00:12:26.570 --> 00:12:28.002 Within blessed to have

NOTE Confidence: 0.7442109

00:12:28.002 --> 00:12:29.434 already Nikolai in myself.

NOTE Confidence: 0.7442109

00:12:29.440 --> 00:12:31.582 Within single, fewer a few weeks

NOTE Confidence: 0.7442109

00:12:31.582 --> 00:12:34.096 ago on this ground round and I

NOTE Confidence: 0.7442109

00:12:34.096 --> 00:12:36.112 guess that you know probably most

NOTE Confidence: 0.7442109

00:12:36.112 --> 00:12:38.769 of the members of the team already.

NOTE Confidence: 0.7442109

00:12:38.770 --> 00:12:42.298 That on our side and that any color without

NOTE Confidence: 0.7442109

00:12:42.298 --> 00:12:45.557 self on universe recruit Rory share is.

NOTE Confidence: 0.7442109

00:12:45.560 --> 00:12:47.545 Doctor Brokaw from San Francisco
NOTE Confidence: 0.7442109

00:12:47.545 --> 00:12:50.832 and up to it from Trimble that
NOTE Confidence: 0.7442109

00:12:50.832 --> 00:12:53.276 collaboration is basically something
NOTE Confidence: 0.7442109

00:12:53.276 --> 00:12:56.360 that is extremely important for us.
NOTE Confidence: 0.7442109

00:12:56.360 --> 00:12:59.570 And on the translational abside Stephanie
NOTE Confidence: 0.7442109

00:12:59.570 --> 00:13:03.165 for sure that has been instrumental in
NOTE Confidence: 0.7442109

00:13:03.165 --> 00:13:07.070 in the group as well as Manoj Pillai.
NOTE Confidence: 0.7442109

00:13:07.070 --> 00:13:10.838 Next slide, please.
NOTE Confidence: 0.7442109

00:13:10.840 --> 00:13:12.950 So as you may know,
NOTE Confidence: 0.7442109

00:13:12.950 --> 00:13:15.040 in MLP malignancy daughter asked
NOTE Confidence: 0.7442109

00:13:15.040 --> 00:13:17.967 basically 10 years we had a real
NOTE Confidence: 0.7442109

00:13:17.967 --> 00:13:19.877 paradigm shift thanks to the
NOTE Confidence: 0.7442109

00:13:19.877 --> 00:13:21.559 revolution of our understanding
NOTE Confidence: 0.7442109

00:13:21.559 --> 00:13:24.337 of the genomics of the disease.
NOTE Confidence: 0.7442109

00:13:24.340 --> 00:13:27.294 That's been true in acute myeloid leukemia,
NOTE Confidence: 0.7442109

00:13:27.300 --> 00:13:28.988 so that's really fast.

NOTE Confidence: 0.8108151

00:13:32.390 --> 00:13:35.486 Through in the acute myeloid leukemia.

NOTE Confidence: 0.8108151

00:13:35.490 --> 00:13:38.080 Then in my dysplastic syndrome,

NOTE Confidence: 0.8108151

00:13:38.080 --> 00:13:40.272 but is basically representative

NOTE Confidence: 0.8108151

00:13:40.272 --> 00:13:44.553 of what we have seen also in our

NOTE Confidence: 0.8108151

00:13:44.553 --> 00:13:46.866 knowledge of my wife, activities,

NOTE Confidence: 0.8108151

00:13:46.866 --> 00:13:49.446 orders, or bone marrow failures,

NOTE Confidence: 0.8108151

00:13:49.450 --> 00:13:52.040 for example, and this revolution,

NOTE Confidence: 0.8108151

00:13:52.040 --> 00:13:55.136 in our understanding of the disease,

NOTE Confidence: 0.8108151

00:13:55.140 --> 00:13:57.243 translated more recently.

NOTE Confidence: 0.8108151

00:13:57.243 --> 00:14:00.748 And we can switch style.

NOTE Confidence: 0.8108151

00:14:00.750 --> 00:14:04.710 Um, in a boarding shift also in the

NOTE Confidence: 0.8108151

00:14:04.710 --> 00:14:07.954 management of this disease and since

NOTE Confidence: 0.8108151

00:14:07.954 --> 00:14:11.821 2017 we add more approval than over

NOTE Confidence: 0.8108151

00:14:11.821 --> 00:14:15.643 the last 2025 years that goes with

NOTE Confidence: 0.8108151

00:14:15.643 --> 00:14:20.410 basically drug at R agnostic of any.

NOTE Confidence: 0.8108151

00:14:20.410 --> 00:14:22.558 Potential genomic amenities such
NOTE Confidence: 0.8108151

00:14:22.558 --> 00:14:26.447 as the CP351 for example or more
NOTE Confidence: 0.8108151

00:14:26.447 --> 00:14:28.739 recently than 8:00 o'clock,
NOTE Confidence: 0.8108151

00:14:28.740 --> 00:14:32.324 but also drug that are no standard of
NOTE Confidence: 0.8108151

00:14:32.324 --> 00:14:35.950 care for basically mutated diseases,
NOTE Confidence: 0.8108151

00:14:35.950 --> 00:14:39.835 such as flat 3 mutated AML or,
NOTE Confidence: 0.8108151

00:14:39.840 --> 00:14:42.056 potentially IDH mutated diseases.
NOTE Confidence: 0.8108151

00:14:42.056 --> 00:14:44.275 Interestingly, this revolution that
NOTE Confidence: 0.8108151

00:14:44.275 --> 00:14:47.605 started with the access my leukemia,
NOTE Confidence: 0.8108151

00:14:47.610 --> 00:14:50.380 we're starting to see seeing,
NOTE Confidence: 0.8108151

00:14:50.380 --> 00:14:51.396 speaking up.
NOTE Confidence: 0.8108151

00:14:51.396 --> 00:14:53.428 Also, in multiple packages,
NOTE Confidence: 0.8108151

00:14:53.430 --> 00:14:56.184 orders with the recent approval of
NOTE Confidence: 0.8108151

00:14:56.184 --> 00:14:59.629 Fedratinib as well as with my dysplastic
NOTE Confidence: 0.8108151

00:14:59.629 --> 00:15:02.169 syndrome with recently the approach
NOTE Confidence: 0.8108151

00:15:02.169 --> 00:15:05.009 the TGF beta inhibitor spider step

NOTE Confidence: 0.8108151

00:15:05.009 --> 00:15:10.290 as well at the oral decide to be in.

NOTE Confidence: 0.8108151

00:15:10.290 --> 00:15:14.232 Stop all of that is extremely

NOTE Confidence: 0.8108151

00:15:14.232 --> 00:15:18.639 important and allow us to basically.

NOTE Confidence: 0.8108151

00:15:18.640 --> 00:15:21.340 Have a real improvement for or

NOTE Confidence: 0.8108151

00:15:21.340 --> 00:15:22.690 patient regarding prognostic

NOTE Confidence: 0.8108151

00:15:22.690 --> 00:15:24.499 forgetting option of treatment.

NOTE Confidence: 0.8108151

00:15:24.500 --> 00:15:28.559 But we still in situation where a cute smile,

NOTE Confidence: 0.8108151

00:15:28.560 --> 00:15:30.364 leukemias and melodies plastic

NOTE Confidence: 0.8108151

00:15:30.364 --> 00:15:33.070 syndromes are how to treat disease.

NOTE Confidence: 0.8108151

00:15:33.070 --> 00:15:35.160 If you standardize the incidence

NOTE Confidence: 0.8108151

00:15:35.160 --> 00:15:38.030 rate of looking at my leukemia,

NOTE Confidence: 0.8108151

00:15:38.030 --> 00:15:41.649 that's still in the top five of

NOTE Confidence: 0.8108151

00:15:41.649 --> 00:15:44.154 the most deadliest cancer that

NOTE Confidence: 0.8108151

00:15:44.154 --> 00:15:48.078 we have to face in the US and one

NOTE Confidence: 0.8108151

00:15:48.078 --> 00:15:50.646 of the goals that we had.

NOTE Confidence: 0.8108151

00:15:50.650 --> 00:15:53.738 In the group has been to really work

NOTE Confidence: 0.8108151

00:15:53.738 --> 00:15:56.646 at different aspect to try to improve

NOTE Confidence: 0.8108151

00:15:56.646 --> 00:15:59.182 the result of the different treatment

NOTE Confidence: 0.8108151

00:15:59.182 --> 00:16:02.406 and we can switch to the next slide.

NOTE Confidence: 0.8108151

00:16:02.410 --> 00:16:03.790 Uh,

NOTE Confidence: 0.8108151

00:16:03.790 --> 00:16:05.170 and.

NOTE Confidence: 0.8108151

00:16:05.170 --> 00:16:08.236 We really tried to to work from

NOTE Confidence: 0.8108151

00:16:08.236 --> 00:16:11.017 single cell to population research

NOTE Confidence: 0.8108151

00:16:11.017 --> 00:16:14.442 and population outcome and that's

NOTE Confidence: 0.8108151

00:16:14.442 --> 00:16:18.217 just not basically to to to to

NOTE Confidence: 0.8108151

00:16:18.217 --> 00:16:19.833 basically have a stun.

NOTE Confidence: 0.8108151

00:16:19.840 --> 00:16:22.966 But that's really what is the

NOTE Confidence: 0.8108151

00:16:22.966 --> 00:16:25.610 MLP malignancy group going from.

NOTE Confidence: 0.8108151

00:16:25.610 --> 00:16:27.980 Stephanie was mentioning our first

NOTE Confidence: 0.8108151

00:16:27.980 --> 00:16:31.046 result in a single cell sequencing

NOTE Confidence: 0.8108151

00:16:31.046 --> 00:16:33.466 in acute myeloid leukemia.

NOTE Confidence: 0.8108151

00:16:33.470 --> 00:16:37.070 As the researcher Stephanie Ann manner.

NOTE Confidence: 0.8108151

00:16:37.070 --> 00:16:43.558 In the labs around uh. Mouse model of.

NOTE Confidence: 0.8108151

00:16:43.560 --> 00:16:46.400 Testing syndromes RNA for montage

NOTE Confidence: 0.8108151

00:16:46.400 --> 00:16:49.812 to the collaboration that we have

NOTE Confidence: 0.8108151

00:16:49.812 --> 00:16:51.716 with the Cobra Group,

NOTE Confidence: 0.8108151

00:16:51.720 --> 00:16:56.704 led by AMR Nikolai and Rory on

NOTE Confidence: 0.8108151

00:16:56.704 --> 00:16:58.128 outcome research.

NOTE Confidence: 0.8108151

00:16:58.130 --> 00:17:00.550 From a pure clinical research,

NOTE Confidence: 0.8108151

00:17:00.550 --> 00:17:03.586 sense points or group has been

NOTE Confidence: 0.8108151

00:17:03.586 --> 00:17:06.161 instrumental in several key studies

NOTE Confidence: 0.8108151

00:17:06.161 --> 00:17:08.885 that led to approval of these

NOTE Confidence: 0.8108151

00:17:08.885 --> 00:17:11.650 drugs over the last few years,

NOTE Confidence: 0.8108151

00:17:11.650 --> 00:17:15.330 but or portfolio and our goal is really

NOTE Confidence: 0.8108151

00:17:15.330 --> 00:17:19.379 focused on early development of a new agent.

NOTE Confidence: 0.8108151

00:17:19.380 --> 00:17:21.790 Right now click portfolio is

NOTE Confidence: 0.8108151

00:17:21.790 --> 00:17:26.568 roughly 40% of phase one trials.

NOTE Confidence: 0.8108151

00:17:26.570 --> 00:17:28.580 With.

NOTE Confidence: 0.8108151

00:17:28.580 --> 00:17:31.247 Basically a good #6 out of 19

NOTE Confidence: 0.8108151

00:17:31.247 --> 00:17:33.530 active trial that our investigator

NOTE Confidence: 0.8108151

00:17:33.530 --> 00:17:36.692 initiated trial and thanks to all

NOTE Confidence: 0.8108151

00:17:36.692 --> 00:17:39.618 the commitment of the research staff.

NOTE Confidence: 0.8108151

00:17:39.620 --> 00:17:42.626 Thanks to all of the commitment

NOTE Confidence: 0.8108151

00:17:42.626 --> 00:17:45.444 of the different members of Group

NOTE Confidence: 0.8108151

00:17:45.444 --> 00:17:48.308 we right now at a rate of index

NOTE Confidence: 0.8108151

00:17:48.402 --> 00:17:50.907 cases included in clinical trials

NOTE Confidence: 0.8108151

00:17:50.907 --> 00:17:55.301 on main campus that is 15 to 20%.

NOTE Confidence: 0.8108151

00:17:55.301 --> 00:17:57.809 Which is pretty remarkable.

NOTE Confidence: 0.83947045

00:17:57.810 --> 00:18:01.394 We definitely aim to do better and

NOTE Confidence: 0.83947045

00:18:01.394 --> 00:18:04.996 we definitely aim to be able to

NOTE Confidence: 0.83947045

00:18:04.996 --> 00:18:07.948 export the research we're doing from

NOTE Confidence: 0.83947045

00:18:08.050 --> 00:18:11.122 the main campus to different side

NOTE Confidence: 0.83947045

00:18:11.122 --> 00:18:14.974 of the network and be able to add

NOTE Confidence: 0.83947045

00:18:14.974 --> 00:18:18.379 better access for our patients in the

NOTE Confidence: 0.83947045

00:18:18.379 --> 00:18:21.359 network as mentioned by Stephanie,

NOTE Confidence: 0.83947045

00:18:21.360 --> 00:18:25.469 we have pretty efficient and pretty large.

NOTE Confidence: 0.83947045

00:18:25.470 --> 00:18:27.892 Think annotate by bank and I think

NOTE Confidence: 0.83947045

00:18:27.892 --> 00:18:30.135 we can give kudos to Stephanie

NOTE Confidence: 0.83947045

00:18:30.135 --> 00:18:32.767 to each of the exports in 2011,

NOTE Confidence: 0.83947045

00:18:32.770 --> 00:18:35.690 so we're in a decade in right now.

NOTE Confidence: 0.83947045

00:18:35.690 --> 00:18:37.880 We should definitely celebrate about that.

NOTE Confidence: 0.83947045

00:18:37.880 --> 00:18:40.800 And that gives us a lot of leverage,

NOTE Confidence: 0.83947045

00:18:40.800 --> 00:18:44.027 potentially to be able to develop some

NOTE Confidence: 0.83947045

00:18:44.027 --> 00:18:45.410 translation translational research.

NOTE Confidence: 0.83947045

00:18:45.410 --> 00:18:47.930 As well as potentially bringing

NOTE Confidence: 0.83947045

00:18:47.930 --> 00:18:50.450 some collaboration from the outside

NOTE Confidence: 0.83947045

00:18:50.529 --> 00:18:52.513 with pharmaceutical companies as

NOTE Confidence: 0.83947045

00:18:52.513 --> 00:18:55.489 well as from academic centers and
NOTE Confidence: 0.83947045

00:18:55.573 --> 00:18:57.529 go to the next next slide.
NOTE Confidence: 0.83947045

00:18:57.530 --> 00:19:00.260 Just wanted to highlight basically two
NOTE Confidence: 0.83947045

00:19:00.260 --> 00:19:03.580 programs more than two studies to program.
NOTE Confidence: 0.83947045

00:19:03.580 --> 00:19:06.980 Basically going on the first one are the
NOTE Confidence: 0.83947045

00:19:06.980 --> 00:19:10.409 efforts led by armor side and on emerging
NOTE Confidence: 0.83947045

00:19:10.409 --> 00:19:12.736 approaches in my late malignancies
NOTE Confidence: 0.83947045

00:19:12.736 --> 00:19:16.168 and probably Anna does not remember,
NOTE Confidence: 0.83947045

00:19:16.170 --> 00:19:17.670 but I've even.
NOTE Confidence: 0.83947045

00:19:17.670 --> 00:19:20.170 Remember first discussion years ago
NOTE Confidence: 0.83947045

00:19:20.170 --> 00:19:23.487 when we were in Hopkins together
NOTE Confidence: 0.83947045

00:19:23.487 --> 00:19:26.267 around potentially all this knew,
NOTE Confidence: 0.83947045

00:19:26.270 --> 00:19:29.450 you know therapies can be instrumental
NOTE Confidence: 0.83947045

00:19:29.450 --> 00:19:34.610 in or disease disease type, basically.
NOTE Confidence: 0.83947045

00:19:34.610 --> 00:19:37.160 What has been done is basically
NOTE Confidence: 0.83947045

00:19:37.160 --> 00:19:38.435 around the additional,

NOTE Confidence: 0.83947045
00:19:38.440 --> 00:19:38.795 uh,
NOTE Confidence: 0.83947045
00:19:38.795 --> 00:19:39.860 the 1st generation,
NOTE Confidence: 0.83947045
00:19:39.860 --> 00:19:41.990 but also right now the second
NOTE Confidence: 0.83947045
00:19:42.063 --> 00:19:44.997 generation of even the energy agent
NOTE Confidence: 0.83947045
00:19:44.997 --> 00:19:46.953 to conventional conventional therapy.
NOTE Confidence: 0.83947045
00:19:46.960 --> 00:19:50.600 We're right now activating.
NOTE Confidence: 0.83947045
00:19:50.600 --> 00:19:54.872 Very broad induction chemotherapy plus volume
NOTE Confidence: 0.83947045
00:19:54.872 --> 00:20:00.177 up study under the umbrella of a sitter.
NOTE Confidence: 0.83947045
00:20:00.180 --> 00:20:03.694 With the first patient that we hope
NOTE Confidence: 0.83947045
00:20:03.694 --> 00:20:07.258 to include in the next few weeks,
NOTE Confidence: 0.83947045
00:20:07.260 --> 00:20:09.790 we just have finished the,
NOTE Confidence: 0.83947045
00:20:09.790 --> 00:20:10.264 uh,
NOTE Confidence: 0.83947045
00:20:10.264 --> 00:20:13.582 cool on the map plus entinostat NDS
NOTE Confidence: 0.83947045
00:20:13.582 --> 00:20:17.322 trial for the group of patients with
NOTE Confidence: 0.83947045
00:20:17.322 --> 00:20:19.915 mild ***** agent Majestik syndrome
NOTE Confidence: 0.83947045

00:20:19.915 --> 00:20:21.935 failed by accommodating agent,
NOTE Confidence: 0.83947045

00:20:21.940 --> 00:20:24.694 and we are looking forward for
NOTE Confidence: 0.83947045

00:20:24.694 --> 00:20:27.748 this data that has been basically
NOTE Confidence: 0.83947045

00:20:27.748 --> 00:20:31.120 possible to to develop thanks to.
NOTE Confidence: 0.83947045

00:20:31.120 --> 00:20:33.785 Elaboration with Yale Science and
NOTE Confidence: 0.83947045

00:20:33.785 --> 00:20:36.960 that's work with initially TK came.
NOTE Confidence: 0.83947045

00:20:36.960 --> 00:20:40.770 One of us still here and we have also a
NOTE Confidence: 0.83947045

00:20:40.869 --> 00:20:43.894 chronic my leukemia studies sponsored
NOTE Confidence: 0.83947045

00:20:43.894 --> 00:20:48.198 by equal on the addition of bambrough
NOTE Confidence: 0.83947045

00:20:48.198 --> 00:20:51.714 on tyrosine kinase inhibitor for a
NOTE Confidence: 0.83947045

00:20:51.714 --> 00:20:54.942 patient with chronic migraine leukemias,
NOTE Confidence: 0.83947045

00:20:54.942 --> 00:20:57.678 an Axia Resul disease.
NOTE Confidence: 0.83947045

00:20:57.680 --> 00:20:59.135 Beside this trial,
NOTE Confidence: 0.83947045

00:20:59.135 --> 00:21:01.560 we also have been implicated.
NOTE Confidence: 0.83947045

00:21:01.560 --> 00:21:04.000 Basically thanks to our leadership
NOTE Confidence: 0.83947045

00:21:04.000 --> 00:21:07.464 on some of the development of the

NOTE Confidence: 0.83947045

00:21:07.464 --> 00:21:09.809 newest generation of Elon College.

NOTE Confidence: 0.83947045

00:21:09.810 --> 00:21:13.554 Agents such as the T in three inhibitor

NOTE Confidence: 0.83947045

00:21:13.554 --> 00:21:17.733 and we hope to have more results to to

NOTE Confidence: 0.83947045

00:21:17.733 --> 00:21:21.930 show that in the near future next slide.

NOTE Confidence: 0.83947045

00:21:21.930 --> 00:21:25.325 So the the idea hmm DS program?

NOTE Confidence: 0.83947045

00:21:25.330 --> 00:21:28.020 That's something that I already.

NOTE Confidence: 0.83947045

00:21:28.020 --> 00:21:30.560 Presented basically a few weeks

NOTE Confidence: 0.83947045

00:21:30.560 --> 00:21:33.100 ago during the ground rounds,

NOTE Confidence: 0.83947045

00:21:33.100 --> 00:21:35.710 but I definitely like this program

NOTE Confidence: 0.83947045

00:21:35.710 --> 00:21:38.680 as it's really a homegrown program

NOTE Confidence: 0.83947045

00:21:38.680 --> 00:21:42.106 thanks to the work and interaction

NOTE Confidence: 0.83947045

00:21:42.106 --> 00:21:44.279 with Stephanie and Ranjit.

NOTE Confidence: 0.83947045

00:21:44.280 --> 00:21:47.880 So that's really a good example of what

NOTE Confidence: 0.83947045

00:21:47.880 --> 00:21:52.400 we can achieve at at yell working together.

NOTE Confidence: 0.83947045

00:21:52.400 --> 00:21:55.809 We have been able to show how

NOTE Confidence: 0.83947045

00:21:55.809 --> 00:21:58.521 we can exploit the weaknesses
NOTE Confidence: 0.83947045

00:21:58.521 --> 00:22:01.923 of IDH mutated AML in NDS.
NOTE Confidence: 0.83947045

00:22:01.930 --> 00:22:05.250 As you can see.
NOTE Confidence: 0.83947045

00:22:05.250 --> 00:22:08.016 When we have an idea of
NOTE Confidence: 0.83947045

00:22:08.016 --> 00:22:09.860 mutation and the presence
NOTE Confidence: 0.760210000000001

00:22:09.957 --> 00:22:13.565 of two HG in the media that creates
NOTE Confidence: 0.760210000000001

00:22:13.565 --> 00:22:17.129 some braknis phenotype that can be
NOTE Confidence: 0.760210000000001

00:22:17.129 --> 00:22:20.329 potentially targeted by using popped
NOTE Confidence: 0.760210000000001

00:22:20.329 --> 00:22:23.590 inhibitor on the upper right side.
NOTE Confidence: 0.760210000000001

00:22:23.590 --> 00:22:26.536 Can see that treatment with olaparib
NOTE Confidence: 0.760210000000001

00:22:26.536 --> 00:22:30.348 in a primary samples in grafted in
NOTE Confidence: 0.760210000000001

00:22:30.348 --> 00:22:32.692 mice can potentially significantly
NOTE Confidence: 0.760210000000001

00:22:32.692 --> 00:22:35.400 reduced the disease burden in.
NOTE Confidence: 0.760210000000001

00:22:35.400 --> 00:22:39.468 Lisa grafted with acute myeloid leukemia.
NOTE Confidence: 0.760210000000001

00:22:39.470 --> 00:22:43.688 Presenting an IDH mutation including in
NOTE Confidence: 0.760210000000001

00:22:43.688 --> 00:22:48.119 some samples where we already documented

NOTE Confidence: 0.760210000000001
00:22:48.119 --> 00:22:53.362 the resistance to IDH inhibitors in the
NOTE Confidence: 0.760210000000001
00:22:53.362 --> 00:22:57.804 clinic and that led to the step trial.
NOTE Confidence: 0.760210000000001
00:22:57.810 --> 00:23:01.200 Brentley ongoing with right now.
NOTE Confidence: 0.760210000000001
00:23:01.200 --> 00:23:03.438 Six patient included,
NOTE Confidence: 0.760210000000001
00:23:03.438 --> 00:23:05.676 including four at.
NOTE Confidence: 0.760210000000001
00:23:05.680 --> 00:23:09.196 At here with basically the use
NOTE Confidence: 0.760210000000001
00:23:09.196 --> 00:23:12.290 of elaborate the parking meter.
NOTE Confidence: 0.760210000000001
00:23:12.290 --> 00:23:16.583 For a male and MBS patient with IDH mutation.
NOTE Confidence: 0.760210000000001
00:23:16.590 --> 00:23:17.068 Interestingly,
NOTE Confidence: 0.760210000000001
00:23:17.068 --> 00:23:19.936 for the discussion with the tap,
NOTE Confidence: 0.760210000000001
00:23:19.940 --> 00:23:23.628 we've been able to have a patient that
NOTE Confidence: 0.760210000000001
00:23:23.628 --> 00:23:27.110 were not yet exposed to IDH limit,
NOTE Confidence: 0.760210000000001
00:23:27.110 --> 00:23:29.690 or potentially integrating the trial
NOTE Confidence: 0.760210000000001
00:23:29.690 --> 00:23:33.206 with an early evaluation that would also
NOTE Confidence: 0.760210000000001
00:23:33.206 --> 00:23:36.188 potentially to switch to ID age limit,
NOTE Confidence: 0.760210000000001

00:23:36.190 --> 00:23:39.277 or there was no some clearcut benefit
NOTE Confidence: 0.760210000000001

00:23:39.277 --> 00:23:42.798 after a few weeks on treatment, so.
NOTE Confidence: 0.760210000000001

00:23:42.798 --> 00:23:45.186 That's two of the main program
NOTE Confidence: 0.760210000000001

00:23:45.186 --> 00:23:47.320 that we have right now.
NOTE Confidence: 0.760210000000001

00:23:47.320 --> 00:23:49.384 I'm not going to basically talk
NOTE Confidence: 0.760210000000001

00:23:49.384 --> 00:23:51.380 too much about the outcome.
NOTE Confidence: 0.760210000000001

00:23:51.380 --> 00:23:54.859 Research as we we add with basically.
NOTE Confidence: 0.760210000000001

00:23:54.860 --> 00:23:55.272 Nicole,
NOTE Confidence: 0.760210000000001

00:23:55.272 --> 00:23:58.568 I would review of what was going on
NOTE Confidence: 0.760210000000001

00:23:58.568 --> 00:24:02.038 on this Group A few a few weeks ago,
NOTE Confidence: 0.760210000000001

00:24:02.040 --> 00:24:04.707 but as we were discussing we really
NOTE Confidence: 0.760210000000001

00:24:04.707 --> 00:24:08.010 want to be able to to bridge the
NOTE Confidence: 0.760210000000001

00:24:08.010 --> 00:24:10.420 most basic science aspect of it.
NOTE Confidence: 0.760210000000001

00:24:10.420 --> 00:24:13.324 What we're doing in the in the labs
NOTE Confidence: 0.760210000000001

00:24:13.324 --> 00:24:17.710 to this outcome. Research go go ahead.
NOTE Confidence: 0.760210000000001

00:24:17.710 --> 00:24:19.992 We still have a lot of people

NOTE Confidence: 0.760210000000001
00:24:19.992 --> 00:24:22.160 in the results clinical issue.
NOTE Confidence: 0.760210000000001
00:24:22.160 --> 00:24:23.628 Then that's the topic.
NOTE Confidence: 0.760210000000001
00:24:23.628 --> 00:24:26.240 We're not the addressing all of them,
NOTE Confidence: 0.760210000000001
00:24:26.240 --> 00:24:28.406 but some of them are definitely
NOTE Confidence: 0.760210000000001
00:24:28.406 --> 00:24:30.699 on the focus of the group.
NOTE Confidence: 0.760210000000001
00:24:30.700 --> 00:24:32.722 The management of high risk disease
NOTE Confidence: 0.760210000000001
00:24:32.722 --> 00:24:35.520 in AML and MD S complex karyotype.
NOTE Confidence: 0.760210000000001
00:24:35.520 --> 00:24:38.033 NLL mutated or rearrange disease are one
NOTE Confidence: 0.760210000000001
00:24:38.033 --> 00:24:41.076 of the focus of development of the group.
NOTE Confidence: 0.760210000000001
00:24:41.080 --> 00:24:44.044 And I specially Rory is developing
NOTE Confidence: 0.760210000000001
00:24:44.044 --> 00:24:46.020 some different concepts around.
NOTE Confidence: 0.760210000000001
00:24:46.020 --> 00:24:46.772 These lines,
NOTE Confidence: 0.760210000000001
00:24:46.772 --> 00:24:48.276 the optimization of targeted
NOTE Confidence: 0.760210000000001
00:24:48.276 --> 00:24:49.780 therapies and email steropes.
NOTE Confidence: 0.760210000000001
00:24:49.780 --> 00:24:52.788 We talked about that one of the challenges,
NOTE Confidence: 0.760210000000001

00:24:52.790 --> 00:24:54.785 basically that we're still working
NOTE Confidence: 0.760210000000001

00:24:54.785 --> 00:24:57.528 with the disease that is not as
NOTE Confidence: 0.760210000000001

00:24:57.528 --> 00:24:59.556 common as breast or colon cancer,
NOTE Confidence: 0.760210000000001

00:24:59.560 --> 00:25:02.010 and we end up with more combination
NOTE Confidence: 0.760210000000001

00:25:02.010 --> 00:25:04.439 and sequence of agent then patient.
NOTE Confidence: 0.760210000000001

00:25:04.440 --> 00:25:05.968 And that's potentially where
NOTE Confidence: 0.760210000000001

00:25:05.968 --> 00:25:08.260 the interaction with the lab and
NOTE Confidence: 0.760210000000001

00:25:08.327 --> 00:25:10.391 the work that we're doing with
NOTE Confidence: 0.760210000000001

00:25:10.391 --> 00:25:12.340 Stephanie is extreme and mineral.
NOTE Confidence: 0.760210000000001

00:25:12.340 --> 00:25:14.730 Extremely important.
NOTE Confidence: 0.760210000000001

00:25:14.730 --> 00:25:17.262 Targeting of leukemia stem cell looking
NOTE Confidence: 0.760210000000001

00:25:17.262 --> 00:25:18.950 initiating cells and management.
NOTE Confidence: 0.760210000000001

00:25:18.950 --> 00:25:20.914 Measurable residual disease at
NOTE Confidence: 0.760210000000001

00:25:20.914 --> 00:25:23.369 the molecular level is obviously
NOTE Confidence: 0.760210000000001

00:25:23.369 --> 00:25:25.278 something that is on our mind,
NOTE Confidence: 0.760210000000001

00:25:25.280 --> 00:25:27.806 and that's a lot of interaction.

NOTE Confidence: 0.760210000000001
00:25:27.810 --> 00:25:30.264 Also with the transplant group in
NOTE Confidence: 0.760210000000001
00:25:30.264 --> 00:25:32.833 South Therapy Group on our potentially
NOTE Confidence: 0.760210000000001
00:25:32.833 --> 00:25:35.407 to to work around this concept.
NOTE Confidence: 0.760210000000001
00:25:35.410 --> 00:25:37.520 And last but not least,
NOTE Confidence: 0.760210000000001
00:25:37.520 --> 00:25:40.052 before getting to the point where
NOTE Confidence: 0.760210000000001
00:25:40.052 --> 00:25:41.740 we have active disease,
NOTE Confidence: 0.760210000000001
00:25:41.740 --> 00:25:43.120 working on predisposition
NOTE Confidence: 0.760210000000001
00:25:43.120 --> 00:25:44.500 and potentially climb.
NOTE Confidence: 0.760210000000001
00:25:44.500 --> 00:25:45.306 To please,
NOTE Confidence: 0.760210000000001
00:25:45.306 --> 00:25:47.724 this is something that is extremely
NOTE Confidence: 0.760210000000001
00:25:47.724 --> 00:25:49.159 interesting right now with.
NOTE Confidence: 0.760210000000001
00:25:49.160 --> 00:25:52.320 In collaboration we will have.
NOTE Confidence: 0.760210000000001
00:25:52.320 --> 00:25:54.728 With the cardiology group
NOTE Confidence: 0.760210000000001
00:25:54.728 --> 00:25:57.136 and the Generation project,
NOTE Confidence: 0.760210000000001
00:25:57.140 --> 00:26:02.276 I think I have one last slide, so we.
NOTE Confidence: 0.760210000000001

00:26:02.276 --> 00:26:05.900 Feel that we we're pretty blessed in the
NOTE Confidence: 0.815233362857143

00:26:06.003 --> 00:26:08.319 group to have already's.
NOTE Confidence: 0.815233362857143

00:26:08.320 --> 00:26:09.460 Pretty solid foundation,
NOTE Confidence: 0.815233362857143

00:26:09.460 --> 00:26:12.592 but we wanted to do better and that's
NOTE Confidence: 0.815233362857143

00:26:12.592 --> 00:26:14.956 gonna be by leveraging the excellence
NOTE Confidence: 0.815233362857143

00:26:14.956 --> 00:26:17.903 that we have it here the molecular
NOTE Confidence: 0.815233362857143

00:26:17.903 --> 00:26:20.013 biology aspect with basically right
NOTE Confidence: 0.815233362857143

00:26:20.013 --> 00:26:23.140 now are some development in single cell
NOTE Confidence: 0.815233362857143

00:26:23.140 --> 00:26:25.395 sequencing using multi omics approaches
NOTE Confidence: 0.815233362857143

00:26:25.395 --> 00:26:28.435 that can potentially be used in my life
NOTE Confidence: 0.815233362857143

00:26:28.435 --> 00:26:31.350 but not only in my right mind agencies.
NOTE Confidence: 0.815233362857143

00:26:31.350 --> 00:26:33.006 Potential collaboration and avenues
NOTE Confidence: 0.815233362857143

00:26:33.006 --> 00:26:35.076 of collaboration with the yellow.
NOTE Confidence: 0.815233362857143

00:26:35.080 --> 00:26:38.588 Center of immuno oncology.
NOTE Confidence: 0.815233362857143

00:26:38.590 --> 00:26:42.577 And with a group of Marcus mention also to
NOTE Confidence: 0.815233362857143

00:26:42.577 --> 00:26:45.320 potentially work on resistance disease,

NOTE Confidence: 0.815233362857143
00:26:45.320 --> 00:26:48.494 immuno oncology in my redemer agencies
NOTE Confidence: 0.815233362857143
00:26:48.494 --> 00:26:51.781 and the really fruitful and really
NOTE Confidence: 0.815233362857143
00:26:51.781 --> 00:26:54.471 exciting collaboration we have with
NOTE Confidence: 0.815233362857143
00:26:54.471 --> 00:26:57.969 the Copper Group carry gross schalmei.
NOTE Confidence: 0.815233362857143
00:26:57.970 --> 00:27:00.959 With a lot of publication and lots
NOTE Confidence: 0.815233362857143
00:27:00.959 --> 00:27:03.808 more that will come in the next.
NOTE Confidence: 0.815233362857143
00:27:03.810 --> 00:27:04.929 Month and year.
NOTE Confidence: 0.815233362857143
00:27:04.929 --> 00:27:07.167 We want to expand our collaboration.
NOTE Confidence: 0.815233362857143
00:27:07.170 --> 00:27:09.582 That's going to be more collaboration
NOTE Confidence: 0.815233362857143
00:27:09.582 --> 00:27:12.040 and the basic Science Group partners
NOTE Confidence: 0.815233362857143
00:27:12.040 --> 00:27:14.756 like June Liu Shan Quinn Go are
NOTE Confidence: 0.815233362857143
00:27:14.756 --> 00:27:16.786 definitely people that will be more
NOTE Confidence: 0.815233362857143
00:27:16.786 --> 00:27:19.616 and more on the stage with us in more
NOTE Confidence: 0.815233362857143
00:27:19.616 --> 00:27:21.500 portable computers as well as more
NOTE Confidence: 0.815233362857143
00:27:21.565 --> 00:27:24.325 collaboration on the clinical research side.
NOTE Confidence: 0.815233362857143

00:27:24.330 --> 00:27:25.818 Obviously with the BMT
NOTE Confidence: 0.815233362857143

00:27:25.818 --> 00:27:27.306 and cell Therapy Group,
NOTE Confidence: 0.815233362857143

00:27:27.310 --> 00:27:29.175 but also without regard for
NOTE Confidence: 0.815233362857143

00:27:29.175 --> 00:27:30.667 the adolescent young adults,
NOTE Confidence: 0.815233362857143

00:27:30.670 --> 00:27:33.274 and I think that's all I have.
NOTE Confidence: 0.8272981

00:27:34.530 --> 00:27:36.140 Thank you so much tomorrow.
NOTE Confidence: 0.8272981

00:27:36.140 --> 00:27:37.284 This is really awesome,
NOTE Confidence: 0.8272981

00:27:37.284 --> 00:27:39.411 so we'll go straight into our next
NOTE Confidence: 0.8272981

00:27:39.411 --> 00:27:41.166 presentation by Doctor Falls on
NOTE Confidence: 0.8272981

00:27:41.166 --> 00:27:42.900 behalf of Mylan Malignancy's team.
NOTE Confidence: 0.7520586999999999

00:27:44.570 --> 00:27:48.282 Hi, this is Francine and I'd like to
NOTE Confidence: 0.7520586999999999

00:27:48.282 --> 00:27:51.362 thank Stephanie and also Charlie for all
NOTE Confidence: 0.7520586999999999

00:27:51.362 --> 00:27:55.518 of your work to bring us to where we are
NOTE Confidence: 0.7520586999999999

00:27:55.518 --> 00:27:58.394 today with this faculty on the development
NOTE Confidence: 0.7520586999999999

00:27:58.394 --> 00:28:01.418 that we've had in the lymphoma program.
NOTE Confidence: 0.7520586999999999

00:28:01.420 --> 00:28:04.006 So lymphoma program consists of myself,

NOTE Confidence: 0.752058699999999
00:28:04.010 --> 00:28:05.738 Scott Huntington, ERISA, Soupy,
NOTE Confidence: 0.752058699999999
00:28:05.738 --> 00:28:07.463 Shalin, Kothari, Toshin Sethi,
NOTE Confidence: 0.752058699999999
00:28:07.463 --> 00:28:08.756 an Francesco Montanari,
NOTE Confidence: 0.752058699999999
00:28:08.760 --> 00:28:11.784 both of whom have recently joined us.
NOTE Confidence: 0.752058699999999
00:28:11.790 --> 00:28:15.122 Francesca is in Greenwich.
NOTE Confidence: 0.752058699999999
00:28:15.122 --> 00:28:17.296 Next slide. Um?
NOTE Confidence: 0.752058699999999
00:28:17.296 --> 00:28:20.838 So this is the landscape of lymphoma.
NOTE Confidence: 0.752058699999999
00:28:20.840 --> 00:28:23.000 So lymphoma really is many different
NOTE Confidence: 0.752058699999999
00:28:23.000 --> 00:28:24.885 diseases, and that's a challenge for
NOTE Confidence: 0.752058699999999
00:28:24.885 --> 00:28:27.699 us as a group with limited resources.
NOTE Confidence: 0.752058699999999
00:28:27.700 --> 00:28:30.220 Terms of trying to figure out how
NOTE Confidence: 0.752058699999999
00:28:30.220 --> 00:28:32.318 we focus this clinical trial effort.
NOTE Confidence: 0.752058699999999
00:28:32.318 --> 00:28:35.502 So it turns out that out of the 21,000
NOTE Confidence: 0.752058699999999
00:28:35.502 --> 00:28:38.169 cases of cancer in Connecticut per year,
NOTE Confidence: 0.752058699999999
00:28:38.170 --> 00:28:40.277 there are about 900 plus or minus
NOTE Confidence: 0.752058699999999

00:28:40.277 --> 00:28:42.499 cases of non Hodgkin's lymphoma.
NOTE Confidence: 0.7520586999999999

00:28:42.500 --> 00:28:44.535 So that's really our denominator
NOTE Confidence: 0.7520586999999999

00:28:44.535 --> 00:28:46.942 population in our efforts are to
NOTE Confidence: 0.7520586999999999

00:28:46.942 --> 00:28:49.063 try to get many of these patients.
NOTE Confidence: 0.7520586999999999

00:28:49.070 --> 00:28:50.454 Want to clinical trials?
NOTE Confidence: 0.7520586999999999

00:28:50.454 --> 00:28:53.258 If you look at the curve at the
NOTE Confidence: 0.7520586999999999

00:28:53.258 --> 00:28:55.533 bottom you can see the frequency of
NOTE Confidence: 0.7520586999999999

00:28:55.533 --> 00:28:58.123 the different types of non Hodgkin's
NOTE Confidence: 0.7520586999999999

00:28:58.123 --> 00:29:01.126 lymphoma with diffuse large B cell lymphoma,
NOTE Confidence: 0.7520586999999999

00:29:01.126 --> 00:29:01.932 follicular lymphoma,
NOTE Confidence: 0.7520586999999999

00:29:01.932 --> 00:29:04.350 the low grade marginal zone lymphoma
NOTE Confidence: 0.7520586999999999

00:29:04.413 --> 00:29:06.315 is being the most common subtypes,
NOTE Confidence: 0.7520586999999999

00:29:06.320 --> 00:29:07.457 and T cell,
NOTE Confidence: 0.7520586999999999

00:29:07.457 --> 00:29:09.352 lymphoma and mantle and mantle
NOTE Confidence: 0.7520586999999999

00:29:09.352 --> 00:29:11.200 cell lymphoma and burkas are.
NOTE Confidence: 0.7520586999999999

00:29:11.200 --> 00:29:13.264 You can see are rare compared

NOTE Confidence: 0.752058699999999
00:29:13.264 --> 00:29:15.320 to these other common subtypes.
NOTE Confidence: 0.752058699999999
00:29:15.320 --> 00:29:17.640 Next slide.
NOTE Confidence: 0.752058699999999
00:29:17.640 --> 00:29:19.998 Um, so the unresolved political issues,
NOTE Confidence: 0.752058699999999
00:29:20.000 --> 00:29:20.670 of course,
NOTE Confidence: 0.752058699999999
00:29:20.670 --> 00:29:23.015 are how we make sense of 90
NOTE Confidence: 0.752058699999999
00:29:23.015 --> 00:29:25.217 different subtypes of lymphoma and
NOTE Confidence: 0.752058699999999
00:29:25.217 --> 00:29:27.462 divide those into general themes.
NOTE Confidence: 0.752058699999999
00:29:27.470 --> 00:29:28.703 For clinical trials,
NOTE Confidence: 0.752058699999999
00:29:28.703 --> 00:29:31.169 I'll talk a little bit about
NOTE Confidence: 0.752058699999999
00:29:31.169 --> 00:29:32.569 that in a minute,
NOTE Confidence: 0.752058699999999
00:29:32.570 --> 00:29:33.596 but you know,
NOTE Confidence: 0.752058699999999
00:29:33.596 --> 00:29:35.648 we do have diseases where the
NOTE Confidence: 0.752058699999999
00:29:35.648 --> 00:29:38.039 modern regimes pretty much are OK
NOTE Confidence: 0.752058699999999
00:29:38.039 --> 00:29:40.019 in terms of producing favorable
NOTE Confidence: 0.752058699999999
00:29:40.095 --> 00:29:42.007 outcomes for these patients,
NOTE Confidence: 0.752058699999999

00:29:42.010 --> 00:29:44.368 but there are within these more
NOTE Confidence: 0.7520586999999999

00:29:44.368 --> 00:29:45.940 favorable subgroups of patients.
NOTE Confidence: 0.7520586999999999

00:29:45.940 --> 00:29:48.358 Those patients with high risk molecular.
NOTE Confidence: 0.7520586999999999

00:29:48.360 --> 00:29:50.170 Features that continue to fail
NOTE Confidence: 0.7520586999999999

00:29:50.170 --> 00:29:51.980 conventional therapy and would be
NOTE Confidence: 0.7520586999999999

00:29:52.037 --> 00:29:53.817 subjects for novel clinical trials
NOTE Confidence: 0.7520586999999999

00:29:53.817 --> 00:29:56.110 and those include double hit diffuse,
NOTE Confidence: 0.7520586999999999

00:29:56.110 --> 00:29:58.020 large B cell lymphoma and
NOTE Confidence: 0.7520586999999999

00:29:58.020 --> 00:30:00.250 one of the things that we.
NOTE Confidence: 0.7520586999999999

00:30:00.250 --> 00:30:02.658 Done with that disease is to combine
NOTE Confidence: 0.7520586999999999

00:30:02.658 --> 00:30:04.860 dose adjusted epoch with Lenalidomide.
NOTE Confidence: 0.7520586999999999

00:30:04.860 --> 00:30:05.622 In addition,
NOTE Confidence: 0.7520586999999999

00:30:05.622 --> 00:30:08.289 we have some patients with low risk
NOTE Confidence: 0.7520586999999999

00:30:08.289 --> 00:30:10.245 lymphoma where we could actually
NOTE Confidence: 0.7520586999999999

00:30:10.245 --> 00:30:12.943 test D escalation of therapy and a
NOTE Confidence: 0.7520586999999999

00:30:12.943 --> 00:30:15.229 good example of that is classical

NOTE Confidence: 0.752058699999999
00:30:15.229 --> 00:30:17.148 Hodgkin's disease and I'm going
NOTE Confidence: 0.752058699999999
00:30:17.148 --> 00:30:19.068 to show you another example.
NOTE Confidence: 0.752058699999999
00:30:19.070 --> 00:30:21.230 For diffuse large B cell lymphoma
NOTE Confidence: 0.752058699999999
00:30:21.230 --> 00:30:23.550 we also have histologies where the
NOTE Confidence: 0.752058699999999
00:30:23.550 --> 00:30:25.590 modern regiments are in ineffective,
NOTE Confidence: 0.752058699999999
00:30:25.590 --> 00:30:27.610 pretty much inadequate for these
NOTE Confidence: 0.752058699999999
00:30:27.610 --> 00:30:29.226 aggressive patients such as
NOTE Confidence: 0.752058699999999
00:30:29.226 --> 00:30:30.828 the T cell lymphoma's.
NOTE Confidence: 0.752058699999999
00:30:30.830 --> 00:30:32.906 The piece of distributing mantle cell
NOTE Confidence: 0.752058699999999
00:30:32.906 --> 00:30:34.781 lymphoma's and the post transplant
NOTE Confidence: 0.752058699999999
00:30:34.781 --> 00:30:36.059 lymphoproliferative disorders so
NOTE Confidence: 0.752058699999999
00:30:36.059 --> 00:30:38.615 in these cases where are trying
NOTE Confidence: 0.752058699999999
00:30:38.675 --> 00:30:40.435 to incorporate novel agents into
NOTE Confidence: 0.752058699999999
00:30:40.435 --> 00:30:42.612 the frontline but also trying to
NOTE Confidence: 0.752058699999999
00:30:42.612 --> 00:30:44.672 figure out how to incorporate
NOTE Confidence: 0.752058699999999

00:30:44.672 --> 00:30:46.708 allogeneic stem cell transplant and
NOTE Confidence: 0.752058699999999

00:30:46.708 --> 00:30:48.640 the newer car T cell therapies,
NOTE Confidence: 0.752058699999999

00:30:48.640 --> 00:30:50.590 would love to use molecular and
NOTE Confidence: 0.752058699999999

00:30:50.590 --> 00:30:52.379 genetic profiling in these diseases
NOTE Confidence: 0.752058699999999

00:30:52.379 --> 00:30:54.509 to select patients rationally for
NOTE Confidence: 0.752058699999999

00:30:54.509 --> 00:30:56.213 pathway directed clinical trials,
NOTE Confidence: 0.752058699999999

00:30:56.220 --> 00:30:58.488 and those efforts are now underway
NOTE Confidence: 0.752058699999999

00:30:58.488 --> 00:31:00.999 thanks to the work of Stephanie.
NOTE Confidence: 0.752058699999999

00:31:01.000 --> 00:31:05.136 To get our tissue bank up and running.
NOTE Confidence: 0.85370207

00:31:05.140 --> 00:31:09.040 Sorry sorry, OK next slide.
NOTE Confidence: 0.85370207

00:31:09.040 --> 00:31:11.290 So, um, just touching on how
NOTE Confidence: 0.85370207

00:31:11.290 --> 00:31:12.415 we're deescalating therapy.
NOTE Confidence: 0.85370207

00:31:12.420 --> 00:31:14.852 This is a really great example of a
NOTE Confidence: 0.85370207

00:31:14.852 --> 00:31:17.636 trial that Scott has opened for relapsed
NOTE Confidence: 0.85370207

00:31:17.636 --> 00:31:19.746 aggressive B cell lymphoma's where
NOTE Confidence: 0.85370207

00:31:19.821 --> 00:31:22.197 we have a non chemotherapy approach.

NOTE Confidence: 0.85370207

00:31:22.200 --> 00:31:24.408 So basically this study involves oral

NOTE Confidence: 0.85370207

00:31:24.408 --> 00:31:27.089 agents of BTK inhibitor and mtor inhibitor,

NOTE Confidence: 0.85370207

00:31:27.090 --> 00:31:29.853 an an image, and it turns out that when

NOTE Confidence: 0.85370207

00:31:29.853 --> 00:31:32.726 you combine these three oral therapies,

NOTE Confidence: 0.85370207

00:31:32.730 --> 00:31:35.124 this is a very effective strategy for

NOTE Confidence: 0.85370207

00:31:35.124 --> 00:31:37.150 patients with aggressive lymphoma who

NOTE Confidence: 0.85370207

00:31:37.150 --> 00:31:39.026 have failed conventional chemotherapy.

NOTE Confidence: 0.85370207

00:31:39.030 --> 00:31:41.918 Some of them have failed transplant as well.

NOTE Confidence: 0.85370207

00:31:41.920 --> 00:31:43.720 On the next slide, Stephanie,

NOTE Confidence: 0.85370207

00:31:43.720 --> 00:31:46.247 you can see an example of one

NOTE Confidence: 0.85370207

00:31:46.247 --> 00:31:47.330 of our patients.

NOTE Confidence: 0.85370207

00:31:47.330 --> 00:31:49.871 It turns out that yell actually has

NOTE Confidence: 0.85370207

00:31:49.871 --> 00:31:51.979 involved the majority of patients that

NOTE Confidence: 0.85370207

00:31:51.979 --> 00:31:54.662 21 patients to date in this trial and

NOTE Confidence: 0.85370207

00:31:54.662 --> 00:31:56.602 responses have been observed among

NOTE Confidence: 0.85370207

00:31:56.602 --> 00:31:58.521 a different subtype of patients.
NOTE Confidence: 0.85370207

00:31:58.521 --> 00:32:00.326 You can see with DL,
NOTE Confidence: 0.85370207

00:32:00.330 --> 00:32:02.130 BCL with low grade lymphoma,
NOTE Confidence: 0.85370207

00:32:02.130 --> 00:32:04.266 mantle cell lymphoma etc and patients
NOTE Confidence: 0.85370207

00:32:04.266 --> 00:32:06.109 with very dramatic responses with
NOTE Confidence: 0.85370207

00:32:06.109 --> 00:32:07.909 large masses and extensive disease.
NOTE Confidence: 0.85370207

00:32:07.910 --> 00:32:10.352 So we were really excited about
NOTE Confidence: 0.85370207

00:32:10.352 --> 00:32:11.166 this approach.
NOTE Confidence: 0.85370207

00:32:11.170 --> 00:32:11.828 And again,
NOTE Confidence: 0.85370207

00:32:11.828 --> 00:32:13.802 we'd all like to start thinking
NOTE Confidence: 0.85370207

00:32:13.802 --> 00:32:15.964 more about oral rather than Ivy
NOTE Confidence: 0.85370207

00:32:15.964 --> 00:32:18.124 therapies for patients that are going
NOTE Confidence: 0.85370207

00:32:18.188 --> 00:32:20.298 to be chronically needing therapy,
NOTE Confidence: 0.85370207

00:32:20.300 --> 00:32:22.848 such as many of our lymphoma patients.
NOTE Confidence: 0.85370207

00:32:22.850 --> 00:32:23.215 Unfortunately,
NOTE Confidence: 0.85370207

00:32:23.215 --> 00:32:25.405 next slide would highlight another approach,

NOTE Confidence: 0.85370207

00:32:25.410 --> 00:32:27.958 which is to take an active drug,

NOTE Confidence: 0.85370207

00:32:27.960 --> 00:32:30.515 look at its resistance mechanisms

NOTE Confidence: 0.85370207

00:32:30.515 --> 00:32:32.559 and come up with.

NOTE Confidence: 0.85370207

00:32:32.560 --> 00:32:34.834 Similar drugs that might be active

NOTE Confidence: 0.85370207

00:32:34.834 --> 00:32:36.350 in resistant mutational settings.

NOTE Confidence: 0.85370207

00:32:36.350 --> 00:32:37.403 In this case.

NOTE Confidence: 0.85370207

00:32:37.403 --> 00:32:39.860 BTK inhibitors are one of our most

NOTE Confidence: 0.85370207

00:32:39.936 --> 00:32:42.785 active newer agents in B cell lymphoma,

NOTE Confidence: 0.85370207

00:32:42.790 --> 00:32:45.219 but most of the failures to these

NOTE Confidence: 0.85370207

00:32:45.219 --> 00:32:47.457 agents are related to the development

NOTE Confidence: 0.85370207

00:32:47.457 --> 00:32:49.701 of specific mutations and now we

NOTE Confidence: 0.85370207

00:32:49.701 --> 00:32:52.152 have these new non covalent BTK

NOTE Confidence: 0.85370207

00:32:52.152 --> 00:32:54.578 inhibitors that actually are able to

NOTE Confidence: 0.85370207

00:32:54.578 --> 00:32:56.668 subvert those mutations and induced

NOTE Confidence: 0.85370207

00:32:56.668 --> 00:32:59.396 responses in patients and this is an

NOTE Confidence: 0.85370207

00:32:59.396 --> 00:33:01.358 agent that we're working with now.

NOTE Confidence: 0.85370207

00:33:01.360 --> 00:33:02.214 Locks 0305.

NOTE Confidence: 0.85370207

00:33:02.214 --> 00:33:04.349 Falls into that category that's

NOTE Confidence: 0.85370207

00:33:04.349 --> 00:33:05.203 highly active.

NOTE Confidence: 0.85370207

00:33:05.210 --> 00:33:07.346 We are currently embarking upon a

NOTE Confidence: 0.85370207

00:33:07.346 --> 00:33:09.611 number of phase two studies that

NOTE Confidence: 0.85370207

00:33:09.611 --> 00:33:11.909 we hope to make available broadly

NOTE Confidence: 0.85370207

00:33:11.909 --> 00:33:13.800 across our care centers looking

NOTE Confidence: 0.85370207

00:33:13.800 --> 00:33:16.250 at a number of different B cell

NOTE Confidence: 0.85370207

00:33:16.250 --> 00:33:18.446 lymphoma is with these novel agents.

NOTE Confidence: 0.85370207

00:33:18.450 --> 00:33:20.710 Next slide.

NOTE Confidence: 0.85370207

00:33:20.710 --> 00:33:21.161 Um,

NOTE Confidence: 0.85370207

00:33:21.161 --> 00:33:23.867 this is some interesting work and

NOTE Confidence: 0.85370207

00:33:23.867 --> 00:33:25.679 translational research done by

NOTE Confidence: 0.85370207

00:33:25.679 --> 00:33:27.589 shelling pathari in our group.

NOTE Confidence: 0.85370207

00:33:27.590 --> 00:33:31.265 So Charlyn is looking at ways of.

NOTE Confidence: 0.85370207

00:33:31.270 --> 00:33:33.170 Dealing with the development of

NOTE Confidence: 0.85370207

00:33:33.170 --> 00:33:35.850 resistance to active agents such as phonetic,

NOTE Confidence: 0.85370207

00:33:35.850 --> 00:33:36.157 LAX,

NOTE Confidence: 0.85370207

00:33:36.157 --> 00:33:38.306 and hear a set of experiments where

NOTE Confidence: 0.85370207

00:33:38.306 --> 00:33:40.817 he has shown that proteasome inhibition

NOTE Confidence: 0.85370207

00:33:40.817 --> 00:33:43.102 is synergistic with phonetic lacks

NOTE Confidence: 0.85370207

00:33:43.102 --> 00:33:45.786 in patients with B cell lymphoma an.

NOTE Confidence: 0.85370207

00:33:45.790 --> 00:33:47.326 In these clinical models,

NOTE Confidence: 0.85370207

00:33:47.326 --> 00:33:50.748 so you can see the bot is mid carve.

NOTE Confidence: 0.85370207

00:33:50.750 --> 00:33:52.660 Is Mebane exacerbated by themselves,

NOTE Confidence: 0.85370207

00:33:52.660 --> 00:33:54.573 which are proteasome inhibitors have

NOTE Confidence: 0.85370207

00:33:54.573 --> 00:33:57.250 some activity to induce a pop ptosis?

NOTE Confidence: 0.85370207

00:33:57.250 --> 00:33:58.790 As does phonetic LAX?

NOTE Confidence: 0.85370207

00:33:58.790 --> 00:34:01.100 But when you combine these agents

NOTE Confidence: 0.85370207

00:34:01.170 --> 00:34:03.480 you can see synergistic activity.

NOTE Confidence: 0.85370207

00:34:03.480 --> 00:34:05.832 And based on this in vitro
NOTE Confidence: 0.85370207

00:34:05.832 --> 00:34:07.890 work that Charlene has done,
NOTE Confidence: 0.85370207

00:34:07.890 --> 00:34:09.895 he's embarking on a seat
NOTE Confidence: 0.85370207

00:34:09.895 --> 00:34:11.499 app sponsored Phase 1,
NOTE Confidence: 0.85370207

00:34:11.500 --> 00:34:13.605 two clinical trial where he's
NOTE Confidence: 0.85370207

00:34:13.605 --> 00:34:15.710 combining genetic LAX with these
NOTE Confidence: 0.85370207

00:34:15.785 --> 00:34:17.925 proteasome inhibitors and we're very
NOTE Confidence: 0.85370207

00:34:17.925 --> 00:34:20.801 excited for Shaolin to get that trial
NOTE Confidence: 0.85370207

00:34:20.801 --> 00:34:23.125 up and running on the next slide,
NOTE Confidence: 0.8098004

00:34:23.130 --> 00:34:25.874 you can see the correlative science that's
NOTE Confidence: 0.8098004

00:34:25.874 --> 00:34:28.338 he's developed around this clinical trial,
NOTE Confidence: 0.8098004

00:34:28.340 --> 00:34:30.380 including a single celled Association
NOTE Confidence: 0.8098004

00:34:30.380 --> 00:34:32.750 to look at these specific BCL,
NOTE Confidence: 0.8098004

00:34:32.750 --> 00:34:34.088 two family members.
NOTE Confidence: 0.8098004

00:34:34.088 --> 00:34:37.386 By Aqua, as well as by mass spec.
NOTE Confidence: 0.8098004

00:34:37.390 --> 00:34:39.390 He's also doing exome sequencing,

NOTE Confidence: 0.8098004

00:34:39.390 --> 00:34:42.438 RNA seek and trying to obtain tissues from

NOTE Confidence: 0.8098004

00:34:42.438 --> 00:34:45.010 these patients for later PDX development.

NOTE Confidence: 0.8098004

00:34:45.010 --> 00:34:47.691 So that's all very exciting and we're

NOTE Confidence: 0.8098004

00:34:47.691 --> 00:34:50.220 really proud of shelling for that.

NOTE Confidence: 0.8098004

00:34:50.220 --> 00:34:53.062 In additional, he's he's doing what other

NOTE Confidence: 0.8098004

00:34:53.062 --> 00:34:56.135 groups are doing to embark on looking for

NOTE Confidence: 0.8098004

00:34:56.135 --> 00:34:59.040 a circulating tumor DNA in these patients,

NOTE Confidence: 0.8098004

00:34:59.040 --> 00:35:02.050 and hopefully some of us will be

NOTE Confidence: 0.8098004

00:35:02.050 --> 00:35:04.580 able to incorporate that into our.

NOTE Confidence: 0.8098004

00:35:04.580 --> 00:35:09.428 A disease group studies as well next slide.

NOTE Confidence: 0.8098004

00:35:09.430 --> 00:35:11.926 So and then the last thing I want

NOTE Confidence: 0.8098004

00:35:11.926 --> 00:35:14.128 to mention is exciting work that

NOTE Confidence: 0.8098004

00:35:14.128 --> 00:35:16.840 Charlene is doing with the Cats lab

NOTE Confidence: 0.8098004

00:35:16.840 --> 00:35:19.138 to use a different approach called

NOTE Confidence: 0.8098004

00:35:19.138 --> 00:35:21.014 protest back to target antiapoptotic

NOTE Confidence: 0.8098004

00:35:21.014 --> 00:35:22.100 protein proteins potentially,
NOTE Confidence: 0.8098004

00:35:22.100 --> 00:35:24.134 but their critic benefit soap Protex
NOTE Confidence: 0.8098004

00:35:24.134 --> 00:35:25.905 basically is a hetero bifunctional
NOTE Confidence: 0.8098004

00:35:25.905 --> 00:35:27.329 small molecule that consists
NOTE Confidence: 0.8098004

00:35:27.329 --> 00:35:29.700 of a linker and two warheads.
NOTE Confidence: 0.8098004

00:35:29.700 --> 00:35:32.080 One of them binding to the target
NOTE Confidence: 0.8098004

00:35:32.080 --> 00:35:35.258 protein such as the BCL two and the other
NOTE Confidence: 0.8098004

00:35:35.258 --> 00:35:37.520 recruiting the E3 ligase to basically
NOTE Confidence: 0.8098004

00:35:37.520 --> 00:35:39.914 leads to the degradation of that.
NOTE Confidence: 0.8098004

00:35:39.920 --> 00:35:40.285 Protein,
NOTE Confidence: 0.8098004

00:35:40.285 --> 00:35:43.205 so we're looking forward to this work coming
NOTE Confidence: 0.8098004

00:35:43.205 --> 00:35:46.058 to fruition in the clinic in the future.
NOTE Confidence: 0.8098004

00:35:46.060 --> 00:35:48.060 Next slide.
NOTE Confidence: 0.8098004

00:35:48.060 --> 00:35:50.160 Just highlights some of the work
NOTE Confidence: 0.8098004

00:35:50.160 --> 00:35:52.333 that Scott has done working with
NOTE Confidence: 0.8098004

00:35:52.333 --> 00:35:54.783 the Copper Group to look at at

NOTE Confidence: 0.8098004

00:35:54.783 --> 00:35:56.959 outcomes in patients with lymphoma.

NOTE Confidence: 0.8098004

00:35:56.960 --> 00:35:59.522 And so Scott has done a number

NOTE Confidence: 0.8098004

00:35:59.522 --> 00:36:01.419 of studies including these two,

NOTE Confidence: 0.8098004

00:36:01.420 --> 00:36:03.412 one of which shows that patients

NOTE Confidence: 0.8098004

00:36:03.412 --> 00:36:06.498 with who are older than 80 have a

NOTE Confidence: 0.8098004

00:36:06.498 --> 00:36:08.190 higher frequency of discontinuing

NOTE Confidence: 0.8098004

00:36:08.190 --> 00:36:09.950 active therapies like a brute,

NOTE Confidence: 0.8098004

00:36:09.950 --> 00:36:12.176 not within the first 180 days.

NOTE Confidence: 0.8098004

00:36:12.180 --> 00:36:15.636 So obviously one has to go back and look

NOTE Confidence: 0.8098004

00:36:15.636 --> 00:36:19.069 at why that is and ways that we can.

NOTE Confidence: 0.8098004

00:36:19.070 --> 00:36:21.122 Alter that therapy so those patients

NOTE Confidence: 0.8098004

00:36:21.122 --> 00:36:23.401 can continue to be treated and then

NOTE Confidence: 0.8098004

00:36:23.401 --> 00:36:25.752 also Scott has done a lot of work

NOTE Confidence: 0.8098004

00:36:25.752 --> 00:36:27.372 with cost effectiveness and this

NOTE Confidence: 0.8098004

00:36:27.372 --> 00:36:29.630 is just one of his studies looking

NOTE Confidence: 0.8098004

00:36:29.630 --> 00:36:31.230 at different treatments for CLL.

NOTE Confidence: 0.8098004

00:36:31.230 --> 00:36:32.830 Getting a brute nip upfront

NOTE Confidence: 0.8098004

00:36:32.830 --> 00:36:34.430 versus getting it later on.

NOTE Confidence: 0.8098004

00:36:34.430 --> 00:36:34.998 So again,

NOTE Confidence: 0.8098004

00:36:34.998 --> 00:36:36.702 Scott has presented some of this

NOTE Confidence: 0.8098004

00:36:36.702 --> 00:36:38.590 work at the national meetings.

NOTE Confidence: 0.8098004

00:36:38.590 --> 00:36:41.128 Then there are a number of

NOTE Confidence: 0.8098004

00:36:41.128 --> 00:36:42.820 studies ongoing with copper.

NOTE Confidence: 0.8098004

00:36:42.820 --> 00:36:46.303 Next slide will then segue us into T cell.

NOTE Confidence: 0.8098004

00:36:46.310 --> 00:36:48.250 Lymphoma is T cell lymphoma.

NOTE Confidence: 0.8098004

00:36:48.250 --> 00:36:50.175 Is overall are heterogeneous as

NOTE Confidence: 0.8098004

00:36:50.175 --> 00:36:53.228 arviso bomas and tend not to do as

NOTE Confidence: 0.8098004

00:36:53.228 --> 00:36:54.983 well with conventional therapies as

NOTE Confidence: 0.8098004

00:36:54.983 --> 00:36:57.822 you can see in the outcomes curve

NOTE Confidence: 0.8098004

00:36:57.822 --> 00:36:59.882 progression free survival in median

NOTE Confidence: 0.8098004

00:36:59.890 --> 00:37:02.606 survival is poor for many of these.

NOTE Confidence: 0.8098004

00:37:02.610 --> 00:37:05.018 Aggressive T cell subtypes.

NOTE Confidence: 0.8098004

00:37:05.018 --> 00:37:06.824 The next slide.

NOTE Confidence: 0.8098004

00:37:06.830 --> 00:37:08.720 Highlights one of the things that

NOTE Confidence: 0.8098004

00:37:08.720 --> 00:37:10.919 we've been trying to do so patients

NOTE Confidence: 0.8098004

00:37:10.919 --> 00:37:12.963 with T cell lymphoma get chop based

NOTE Confidence: 0.8098004

00:37:13.023 --> 00:37:15.297 chemotherapy upfront and only a small

NOTE Confidence: 0.8098004

00:37:15.297 --> 00:37:17.488 percentage of them actually are cured.

NOTE Confidence: 0.8098004

00:37:17.488 --> 00:37:18.490 With this approach,

NOTE Confidence: 0.8098004

00:37:18.490 --> 00:37:20.476 patients would go on to an

NOTE Confidence: 0.8098004

00:37:20.476 --> 00:37:22.189 autologous stem cell transplant if

NOTE Confidence: 0.8098004

00:37:22.189 --> 00:37:23.809 they have a complete remission,

NOTE Confidence: 0.8098004

00:37:23.810 --> 00:37:25.658 but it turns out that when

NOTE Confidence: 0.8098004

00:37:25.658 --> 00:37:27.480 you look at registry studies,

NOTE Confidence: 0.8098004

00:37:27.480 --> 00:37:29.466 one of which we conducted here,

NOTE Confidence: 0.8098004

00:37:29.470 --> 00:37:31.135 only about 25% of patients

NOTE Confidence: 0.8098004

00:37:31.135 --> 00:37:32.800 upfront ever make a transplant.
NOTE Confidence: 0.8620923

00:37:32.800 --> 00:37:35.502 The reason being that many of those
NOTE Confidence: 0.8620923

00:37:35.502 --> 00:37:37.929 patients don't have a good remission.
NOTE Confidence: 0.8620923

00:37:37.930 --> 00:37:40.495 And so this is a study that I worked
NOTE Confidence: 0.8620923

00:37:40.495 --> 00:37:43.095 on with tar Sheen and this study
NOTE Confidence: 0.8620923

00:37:43.095 --> 00:37:45.480 is hopefully going to get started
NOTE Confidence: 0.8620923

00:37:45.480 --> 00:37:47.934 very soon where we combined Mogamu
NOTE Confidence: 0.8620923

00:37:47.934 --> 00:37:49.843 Lizum app with upfront chemotherapy.
NOTE Confidence: 0.8620923

00:37:49.843 --> 00:37:52.010 In this case, epoch for patients
NOTE Confidence: 0.8620923

00:37:52.010 --> 00:37:53.810 with aggressive T cell lymphoma.
NOTE Confidence: 0.8620923

00:37:53.810 --> 00:37:55.940 The idea being that Mogamulizumab is
NOTE Confidence: 0.8620923

00:37:55.940 --> 00:37:58.102 a CCR four monoclonal antibody that
NOTE Confidence: 0.8620923

00:37:58.102 --> 00:38:00.798 targets both tumor cells at but also more
NOTE Confidence: 0.8620923

00:38:00.862 --> 00:38:03.557 importantly T regs in the micro environment,
NOTE Confidence: 0.8620923

00:38:03.560 --> 00:38:05.540 so we're hoping that there's
NOTE Confidence: 0.8620923

00:38:05.540 --> 00:38:07.520 going to be an interaction.

NOTE Confidence: 0.8620923

00:38:07.520 --> 00:38:09.928 Both in the micro environment as well as

NOTE Confidence: 0.8620923

00:38:09.928 --> 00:38:11.680 potential synergy with the tumor cells.

NOTE Confidence: 0.8620923

00:38:11.680 --> 00:38:13.456 When this is combined with chemotherapy,

NOTE Confidence: 0.8620923

00:38:13.460 --> 00:38:16.528 I don't have a slide to show you this, but,

NOTE Confidence: 0.8620923

00:38:16.528 --> 00:38:19.712 uh, she has also developed some very nice

NOTE Confidence: 0.8620923

00:38:19.712 --> 00:38:22.245 correlative studies to go along with this.

NOTE Confidence: 0.8620923

00:38:22.250 --> 00:38:24.698 The next slide.

NOTE Confidence: 0.8620923

00:38:24.700 --> 00:38:27.060 Will take you into the world of relapsed

NOTE Confidence: 0.8620923

00:38:27.060 --> 00:38:29.315 T cell lymphoma and just to demonstrate

NOTE Confidence: 0.8620923

00:38:29.315 --> 00:38:32.517 to you the work of our group to look at

NOTE Confidence: 0.8620923

00:38:32.517 --> 00:38:34.378 a number of different agents targeting

NOTE Confidence: 0.8620923

00:38:34.378 --> 00:38:36.286 a number of different pathways that

NOTE Confidence: 0.8620923

00:38:36.286 --> 00:38:38.427 are relevant and some of these studies.

NOTE Confidence: 0.8620923

00:38:38.430 --> 00:38:40.617 Yale has been the top one or or two

NOTE Confidence: 0.8620923

00:38:40.617 --> 00:38:43.198 in terms of accrual for these studies

NOTE Confidence: 0.8620923

00:38:43.198 --> 00:38:45.078 nationwide and these are novel

NOTE Confidence: 0.8620923

00:38:45.078 --> 00:38:47.486 agents and I'll touch on a couple of

NOTE Confidence: 0.8620923

00:38:47.486 --> 00:38:50.418 them in the next slide or two.

NOTE Confidence: 0.8620923

00:38:50.420 --> 00:38:57.090 Um, go back and this is this is next slide.

NOTE Confidence: 0.8620923

00:38:57.090 --> 00:38:57.441 OK,

NOTE Confidence: 0.8620923

00:38:57.441 --> 00:38:59.547 this is tipifarnib which is a

NOTE Confidence: 0.8620923

00:38:59.547 --> 00:39:00.249 farnesyltransferase inhibitor,

NOTE Confidence: 0.8620923

00:39:00.250 --> 00:39:03.074 but it turns out that that it also

NOTE Confidence: 0.8620923

00:39:03.074 --> 00:39:05.691 down regulates CX CL 12 which is

NOTE Confidence: 0.8620923

00:39:05.691 --> 00:39:07.526 in the micro environment patients

NOTE Confidence: 0.8620923

00:39:07.607 --> 00:39:10.143 who have expression of CX CL 12 in

NOTE Confidence: 0.8620923

00:39:10.143 --> 00:39:11.924 the micro environment don't do as

NOTE Confidence: 0.8620923

00:39:11.924 --> 00:39:14.554 well as you can see on this survival

NOTE Confidence: 0.8620923

00:39:14.554 --> 00:39:17.092 curve and we've had some incredibly

NOTE Confidence: 0.8620923

00:39:17.092 --> 00:39:18.998 dramatic responses using this single

NOTE Confidence: 0.8620923

00:39:18.998 --> 00:39:21.308 oral agent and some of our patients

NOTE Confidence: 0.8620923

00:39:21.310 --> 00:39:23.648 such as this gentleman who has failed

NOTE Confidence: 0.8620923

00:39:23.648 --> 00:39:25.112 multiple therapies in autologous

NOTE Confidence: 0.8620923

00:39:25.112 --> 00:39:27.536 transplant that this is really salvage.

NOTE Confidence: 0.8620923

00:39:27.540 --> 00:39:29.752 A lot of people were hoping to

NOTE Confidence: 0.8620923

00:39:29.752 --> 00:39:31.802 initiate some Iits with this molecule

NOTE Confidence: 0.8620923

00:39:31.802 --> 00:39:33.866 in the next couple of months.

NOTE Confidence: 0.8620923

00:39:33.870 --> 00:39:35.530 Next slide shows you another

NOTE Confidence: 0.8620923

00:39:35.530 --> 00:39:36.858 approach with micro RNA,

NOTE Confidence: 0.8620923

00:39:36.860 --> 00:39:39.020 so this is the first in man study

NOTE Confidence: 0.8620923

00:39:39.020 --> 00:39:41.414 of this micro RNA which targets a

NOTE Confidence: 0.8620923

00:39:41.414 --> 00:39:43.860 number of different types of lymphoma.

NOTE Confidence: 0.8620923

00:39:43.860 --> 00:39:46.205 We put a number of patients with

NOTE Confidence: 0.8620923

00:39:46.205 --> 00:39:48.257 cutaneous lymphoma on this trial and

NOTE Confidence: 0.8620923

00:39:48.257 --> 00:39:50.553 you could see responses in pretty much

NOTE Confidence: 0.8620923

00:39:50.623 --> 00:39:52.877 all of the patients that were treated

NOTE Confidence: 0.8620923

00:39:52.877 --> 00:39:54.945 based on these waterfall plots and
NOTE Confidence: 0.8620923

00:39:54.945 --> 00:39:58.110 on the next slide I think is really.
NOTE Confidence: 0.8620923

00:39:58.110 --> 00:40:00.318 One of the most important findings.
NOTE Confidence: 0.8620923

00:40:00.320 --> 00:40:01.421 This micro RNA,
NOTE Confidence: 0.8620923

00:40:01.421 --> 00:40:03.990 which is its activity in HTLV one
NOTE Confidence: 0.8620923

00:40:04.073 --> 00:40:06.548 associated adult T cell leukemia,
NOTE Confidence: 0.8620923

00:40:06.550 --> 00:40:09.161 and again we put the majority of
NOTE Confidence: 0.8620923

00:40:09.161 --> 00:40:11.689 patients in this cohort on this
NOTE Confidence: 0.8620923

00:40:11.689 --> 00:40:14.341 trial and we also initiated the
NOTE Confidence: 0.8620923

00:40:14.341 --> 00:40:16.916 correlative studies that you see below,
NOTE Confidence: 0.8620923

00:40:16.920 --> 00:40:18.990 showing that the molecule directly
NOTE Confidence: 0.8620923

00:40:18.990 --> 00:40:21.490 inhibits the proliferation of ATL cells.
NOTE Confidence: 0.8620923

00:40:21.490 --> 00:40:23.760 Modulates the expression of various
NOTE Confidence: 0.8620923

00:40:23.760 --> 00:40:26.527 activation markers and you can see
NOTE Confidence: 0.8620923

00:40:26.527 --> 00:40:28.627 the changes in proliferation index
NOTE Confidence: 0.8620923

00:40:28.627 --> 00:40:30.929 with this molecule and this is.

NOTE Confidence: 0.8620923

00:40:30.930 --> 00:40:33.066 All samples from our patients that

NOTE Confidence: 0.8620923

00:40:33.066 --> 00:40:35.289 were drawn at different time points,

NOTE Confidence: 0.8620923

00:40:35.290 --> 00:40:37.824 so we're very excited to get this

NOTE Confidence: 0.8620923

00:40:37.824 --> 00:40:38.548 data published.

NOTE Confidence: 0.8625064

00:40:38.550 --> 00:40:42.135 Next slide. Just a couple

NOTE Confidence: 0.8625064

00:40:42.135 --> 00:40:43.635 of other studies initiated.

NOTE Confidence: 0.8625064

00:40:43.640 --> 00:40:45.605 This is another of Pershing

NOTE Confidence: 0.8625064

00:40:45.605 --> 00:40:47.570 study looking at incorporation of

NOTE Confidence: 0.8625064

00:40:47.636 --> 00:40:49.631 pembrolizumab with an active agent

NOTE Confidence: 0.8625064

00:40:49.631 --> 00:40:52.019 Brentuximab dwtin in CD 30 positive

NOTE Confidence: 0.8625064

00:40:52.019 --> 00:40:54.273 T cell lymphoma is and again this

NOTE Confidence: 0.8625064

00:40:54.273 --> 00:40:57.326 is this is her IIT and there are

NOTE Confidence: 0.8625064

00:40:57.326 --> 00:40:58.930 some correlative studies associated

NOTE Confidence: 0.8625064

00:40:59.000 --> 00:41:00.938 with this and the next slide.

NOTE Confidence: 0.8136023

00:41:03.860 --> 00:41:06.156 Yeah, the next slide will segue into

NOTE Confidence: 0.8136023

00:41:06.156 --> 00:41:08.631 some of the efforts that Francesca has
NOTE Confidence: 0.8136023

00:41:08.631 --> 00:41:11.930 looking at in a couple of different areas.
NOTE Confidence: 0.8136023

00:41:11.930 --> 00:41:14.138 In the context of aggressive lymphomas,
NOTE Confidence: 0.8136023

00:41:14.140 --> 00:41:17.068 this is her global T cell consortium study,
NOTE Confidence: 0.8136023

00:41:17.070 --> 00:41:18.880 which she conducted at Columbia
NOTE Confidence: 0.8136023

00:41:18.880 --> 00:41:21.110 and is now brought to Yale,
NOTE Confidence: 0.8136023

00:41:21.110 --> 00:41:23.448 and this is now a randomized phase
NOTE Confidence: 0.8136023

00:41:23.448 --> 00:41:25.809 two study where she's looking at 5:00
NOTE Confidence: 0.8136023

00:41:25.809 --> 00:41:28.724 or oral is incited gene in Rome and
NOTE Confidence: 0.8136023

00:41:28.724 --> 00:41:31.019 Epsom compared to investigators choice.
NOTE Confidence: 0.8136023

00:41:31.020 --> 00:41:33.150 This is a multicenter study.
NOTE Confidence: 0.8136023

00:41:33.150 --> 00:41:35.445 And we're really excited that
NOTE Confidence: 0.8136023

00:41:35.445 --> 00:41:38.519 Francesca has brought this to us and
NOTE Confidence: 0.8136023

00:41:38.519 --> 00:41:40.969 the next slide is another effort in
NOTE Confidence: 0.8136023

00:41:40.969 --> 00:41:43.810 an area that we have not explored.
NOTE Confidence: 0.8136023

00:41:43.810 --> 00:41:46.270 Which is PTLD so post transplant

NOTE Confidence: 0.8136023

00:41:46.270 --> 00:41:47.090 lymphoproliferative disorders.

NOTE Confidence: 0.8136023

00:41:47.090 --> 00:41:48.638 In this study,

NOTE Confidence: 0.8136023

00:41:48.638 --> 00:41:50.702 Francesca is using sequential

NOTE Confidence: 0.8136023

00:41:50.702 --> 00:41:53.274 treatment for patients that are CD

NOTE Confidence: 0.8136023

00:41:53.274 --> 00:41:55.940 20 and CD 30 positive and you can

NOTE Confidence: 0.8136023

00:41:55.940 --> 00:41:58.565 see the scheme for this trial here.

NOTE Confidence: 0.8136023

00:41:58.570 --> 00:42:01.954 This is also an IIT that's being conducted

NOTE Confidence: 0.8136023

00:42:01.954 --> 00:42:04.378 in collaboration with the Mayo Clinic.

NOTE Confidence: 0.8136023

00:42:04.380 --> 00:42:05.264 Would you be a?

NOTE Confidence: 0.8136023

00:42:05.264 --> 00:42:07.653 So I think we have some really nice work

NOTE Confidence: 0.8136023

00:42:07.653 --> 00:42:09.657 from some of our younger investigators

NOTE Confidence: 0.8136023

00:42:09.657 --> 00:42:11.757 and we're very excited about that.

NOTE Confidence: 0.8136023

00:42:11.760 --> 00:42:14.328 The next slide.

NOTE Confidence: 0.8136023

00:42:14.330 --> 00:42:17.106 Is just our summary slide looking at what

NOTE Confidence: 0.8136023

00:42:17.106 --> 00:42:19.443 our future is and where we're hoping

NOTE Confidence: 0.8136023

00:42:19.443 --> 00:42:21.950 to go in the lymphoid malignancy's.
NOTE Confidence: 0.8136023

00:42:21.950 --> 00:42:24.074 So clearly we will benefit from
NOTE Confidence: 0.8136023

00:42:24.074 --> 00:42:25.947 the annotated database that you've
NOTE Confidence: 0.8136023

00:42:25.947 --> 00:42:28.287 heard about and hopefully will be
NOTE Confidence: 0.8136023

00:42:28.287 --> 00:42:30.159 contributing our samples in an
NOTE Confidence: 0.8136023

00:42:30.159 --> 00:42:31.744 ongoing fashion to the biobank.
NOTE Confidence: 0.8136023

00:42:31.750 --> 00:42:34.158 We also need to develop a sequencing
NOTE Confidence: 0.8136023

00:42:34.158 --> 00:42:36.018 platform which we really don't
NOTE Confidence: 0.8136023

00:42:36.018 --> 00:42:37.928 have here at the institution.
NOTE Confidence: 0.8136023

00:42:37.930 --> 00:42:39.378 For lymphoma we're currently
NOTE Confidence: 0.8136023

00:42:39.378 --> 00:42:40.826 sending our samples out,
NOTE Confidence: 0.8136023

00:42:40.830 --> 00:42:43.002 but we certainly would like to
NOTE Confidence: 0.8136023

00:42:43.002 --> 00:42:45.500 do that in the near future.
NOTE Confidence: 0.8136023

00:42:45.500 --> 00:42:47.474 I talked about the biobank and
NOTE Confidence: 0.8136023

00:42:47.474 --> 00:42:48.790 how important that is,
NOTE Confidence: 0.8136023

00:42:48.790 --> 00:42:51.454 but also we're now starting to talk about

NOTE Confidence: 0.8136023

00:42:51.454 --> 00:42:53.069 thematic direction for the program,

NOTE Confidence: 0.8136023

00:42:53.070 --> 00:42:55.275 and one of the areas that we're

NOTE Confidence: 0.8136023

00:42:55.275 --> 00:42:57.998 focusing on at least in T cell lymphoma,

NOTE Confidence: 0.8136023

00:42:58.000 --> 00:42:58.984 as you've seen,

NOTE Confidence: 0.8136023

00:42:58.984 --> 00:43:00.624 is on the micro environment,

NOTE Confidence: 0.8136023

00:43:00.630 --> 00:43:02.185 and you know immunomodulatory strategies

NOTE Confidence: 0.8136023

00:43:02.185 --> 00:43:04.486 that can be used with correlative science

NOTE Confidence: 0.8136023

00:43:04.486 --> 00:43:06.556 in these two cell lymphoma studies,

NOTE Confidence: 0.8136023

00:43:06.560 --> 00:43:07.586 and then finally,

NOTE Confidence: 0.8136023

00:43:07.586 --> 00:43:09.638 I just want to acknowledge the

NOTE Confidence: 0.8136023

00:43:09.638 --> 00:43:10.686 translational science collaborators

NOTE Confidence: 0.8136023

00:43:10.686 --> 00:43:12.961 and this by no means is an

NOTE Confidence: 0.8136023

00:43:12.961 --> 00:43:14.118 exhaustive list of folks,

NOTE Confidence: 0.8136023

00:43:14.120 --> 00:43:16.500 but there have been a number of.

NOTE Confidence: 0.8136023

00:43:16.500 --> 00:43:19.260 Studies that have been funded by both DeLuca

NOTE Confidence: 0.8136023

00:43:19.260 --> 00:43:22.137 as well as other mechanisms for funding,

NOTE Confidence: 0.8136023

00:43:22.140 --> 00:43:24.426 and those include studies done with

NOTE Confidence: 0.8136023

00:43:24.426 --> 00:43:27.028 the Cats lab with Marcus is lab,

NOTE Confidence: 0.8136023

00:43:27.030 --> 00:43:28.910 which is now being engaged

NOTE Confidence: 0.8136023

00:43:28.910 --> 00:43:30.038 with these studies.

NOTE Confidence: 0.8136023

00:43:30.040 --> 00:43:32.302 The Lola slab in pharmacology and

NOTE Confidence: 0.8136023

00:43:32.302 --> 00:43:35.013 even the imaging labs with a nuclear

NOTE Confidence: 0.8136023

00:43:35.013 --> 00:43:37.275 medicine with Doctor Chi and others

NOTE Confidence: 0.8136023

00:43:37.275 --> 00:43:39.440 that I didn't mention as well.

NOTE Confidence: 0.8136023

00:43:39.440 --> 00:43:42.437 So I think we have a very bright future

NOTE Confidence: 0.8136023

00:43:42.437 --> 00:43:45.445 ahead of us in the lymphoid malignancies.

NOTE Confidence: 0.8136023

00:43:45.450 --> 00:43:46.202 Thank you,

NOTE Confidence: 0.8136023

00:43:46.202 --> 00:43:46.578 Stephanie.

NOTE Confidence: 0.8164225

00:43:48.050 --> 00:43:49.630 Thank you for I've jumped.

NOTE Confidence: 0.8164225

00:43:49.630 --> 00:43:51.590 Thank you for seeing that is after

NOTE Confidence: 0.8164225

00:43:51.590 --> 00:43:53.816 you tour Tour de force and lymphoma

NOTE Confidence: 0.8164225

00:43:53.816 --> 00:43:55.808 is so excited about everything that

NOTE Confidence: 0.8164225

00:43:55.872 --> 00:43:58.112 is to come and very excited about

NOTE Confidence: 0.8164225

00:43:58.112 --> 00:43:59.710 our next presentation by Doctor

NOTE Confidence: 0.8164225

00:43:59.710 --> 00:44:01.600 Natalia never eats a on multiple

NOTE Confidence: 0.816422500000001

00:44:01.600 --> 00:44:02.617 myeloma in commodities.

NOTE Confidence: 0.816422500000001

00:44:02.617 --> 00:44:04.990 Stephanie, thank you so much for the

NOTE Confidence: 0.816422500000001

00:44:05.052 --> 00:44:06.816 opportunity to let me present today

NOTE Confidence: 0.816422500000001

00:44:06.816 --> 00:44:09.546 and I would like to echo some of your

NOTE Confidence: 0.816422500000001

00:44:09.546 --> 00:44:11.680 comments and thank thank Charlie for his

NOTE Confidence: 0.816422500000001

00:44:11.680 --> 00:44:13.570 outstanding leadership at the Cancer Center.

NOTE Confidence: 0.816422500000001

00:44:13.570 --> 00:44:15.495 So today I'm happy to present on

NOTE Confidence: 0.816422500000001

00:44:15.495 --> 00:44:17.469 behalf of myeloma team with brief

NOTE Confidence: 0.816422500000001

00:44:17.469 --> 00:44:18.917 clinical and research updates.

NOTE Confidence: 0.816422500000001

00:44:18.920 --> 00:44:20.810 Here's our team myself. Terry Parker.

NOTE Confidence: 0.816422500000001

00:44:20.810 --> 00:44:22.470 Know far Bar and Sabrina.

NOTE Confidence: 0.816422500000001

00:44:22.470 --> 00:44:25.870 Browning as well as Elon Gorshin at Guilford.

NOTE Confidence: 0.816422500000001

00:44:25.870 --> 00:44:27.085 Next slide please.

NOTE Confidence: 0.816422500000001

00:44:27.085 --> 00:44:29.110 I'll start with brief Brecht

NOTE Confidence: 0.816422500000001

00:44:29.110 --> 00:44:30.749 background about the disease.

NOTE Confidence: 0.816422500000001

00:44:30.750 --> 00:44:32.242 As you all know,

NOTE Confidence: 0.816422500000001

00:44:32.242 --> 00:44:35.000 multiple myeloma is the clonal plasma cell

NOTE Confidence: 0.816422500000001

00:44:35.000 --> 00:44:37.664 neoplasm originating in the bone marrow.

NOTE Confidence: 0.816422500000001

00:44:37.670 --> 00:44:39.944 The diagnosis rests on the bone

NOTE Confidence: 0.816422500000001

00:44:39.944 --> 00:44:42.883 marrow biopsy and some of the key

NOTE Confidence: 0.816422500000001

00:44:42.883 --> 00:44:44.679 immunohistochemical stains and protein

NOTE Confidence: 0.816422500000001

00:44:44.679 --> 00:44:47.437 studies on the blood in the urine.

NOTE Confidence: 0.816422500000001

00:44:47.440 --> 00:44:49.470 The ETL pathogenesis of this

NOTE Confidence: 0.816422500000001

00:44:49.470 --> 00:44:51.094 disorder remains largely obscure.

NOTE Confidence: 0.816422500000001

00:44:51.100 --> 00:44:53.140 We know of certain associations,

NOTE Confidence: 0.816422500000001

00:44:53.140 --> 00:44:55.170 such as perhaps antigenic stimulation.

NOTE Confidence: 0.816422500000001

00:44:55.170 --> 00:44:56.022 Role of.

NOTE Confidence: 0.816422500000001
00:44:56.022 --> 00:44:56.874 Pathogenic microbes,
NOTE Confidence: 0.816422500000001
00:44:56.874 --> 00:44:59.004 lipid antigens and other associations
NOTE Confidence: 0.816422500000001
00:44:59.004 --> 00:45:00.848 such as metabolic syndromes,
NOTE Confidence: 0.816422500000001
00:45:00.850 --> 00:45:02.095 diabetes and such,
NOTE Confidence: 0.816422500000001
00:45:02.095 --> 00:45:05.000 but in large majority of patients we
NOTE Confidence: 0.816422500000001
00:45:05.085 --> 00:45:07.941 don't know the cause and much remains
NOTE Confidence: 0.816422500000001
00:45:07.941 --> 00:45:10.528 to be elucidated in this research.
NOTE Confidence: 0.816422500000001
00:45:10.530 --> 00:45:13.158 Next slide, please.
NOTE Confidence: 0.816422500000001
00:45:13.160 --> 00:45:14.396 So as you know,
NOTE Confidence: 0.816422500000001
00:45:14.396 --> 00:45:16.250 the diseases continuum and we know
NOTE Confidence: 0.816422500000001
00:45:16.321 --> 00:45:18.403 that myeloma every case is pre
NOTE Confidence: 0.816422500000001
00:45:18.403 --> 00:45:20.307 preceded by the precursor state
NOTE Confidence: 0.816422500000001
00:45:20.307 --> 00:45:23.019 called M Gus monoclonal gammopathy of
NOTE Confidence: 0.816422500000001
00:45:23.019 --> 00:45:24.720 undetermined significance and after
NOTE Confidence: 0.816422500000001
00:45:24.720 --> 00:45:26.760 years of its presence it progress
NOTE Confidence: 0.816422500000001

00:45:26.760 --> 00:45:29.240 is to the early phase myeloma,
NOTE Confidence: 0.816422500000001

00:45:29.240 --> 00:45:31.110 commonly referred to as small
NOTE Confidence: 0.816422500000001

00:45:31.110 --> 00:45:32.606 during or asymptomatic myeloma.
NOTE Confidence: 0.816422500000001

00:45:32.610 --> 00:45:35.148 But a full blown clinical disease
NOTE Confidence: 0.816422500000001

00:45:35.148 --> 00:45:37.244 which requires active therapy is
NOTE Confidence: 0.816422500000001

00:45:37.244 --> 00:45:39.547 the disease which leads to end organ
NOTE Confidence: 0.816422500000001

00:45:39.547 --> 00:45:41.958 damage in the form of high calcium,
NOTE Confidence: 0.816422500000001

00:45:41.960 --> 00:45:44.270 renal failure, anemia and bone lesions.
NOTE Confidence: 0.816422500000001

00:45:44.270 --> 00:45:46.657 And in the old days we would
NOTE Confidence: 0.816422500000001

00:45:46.657 --> 00:45:48.299 resort to plane X Rays.
NOTE Confidence: 0.816422500000001

00:45:48.300 --> 00:45:48.708 However,
NOTE Confidence: 0.816422500000001

00:45:48.708 --> 00:45:51.156 this has been largely replaced by
NOTE Confidence: 0.816422500000001

00:45:51.156 --> 00:45:52.943 advanced imaging modalities such as
NOTE Confidence: 0.816422500000001

00:45:52.943 --> 00:45:55.360 whole body MRI or Whole Body PET CT scans.
NOTE Confidence: 0.816422500000001

00:45:55.360 --> 00:45:57.340 Next please.
NOTE Confidence: 0.816422500000001

00:45:57.340 --> 00:45:58.615 So once diagnosed,

NOTE Confidence: 0.816422500000001
00:45:58.615 --> 00:46:00.740 the treatment pattern of multiple
NOTE Confidence: 0.816422500000001
00:46:00.740 --> 00:46:02.384 myeloma consists of initial
NOTE Confidence: 0.816422500000001
00:46:02.384 --> 00:46:04.556 induction therapy with usual 3 drug,
NOTE Confidence: 0.816422500000001
00:46:04.560 --> 00:46:07.024 or in 2021 you might choose a four
NOTE Confidence: 0.816422500000001
00:46:07.024 --> 00:46:09.280 drug regimen incorporating some of
NOTE Confidence: 0.816422500000001
00:46:09.280 --> 00:46:11.376 the monoclonal antibodies upfront,
NOTE Confidence: 0.816422500000001
00:46:11.380 --> 00:46:13.380 such as daratumumab inappropriate patients.
NOTE Confidence: 0.816422500000001
00:46:13.380 --> 00:46:16.588 This is then followed by high dose melphalan,
NOTE Confidence: 0.816422500000001
00:46:16.590 --> 00:46:18.595 an autologous stem cell rescue
NOTE Confidence: 0.816422500000001
00:46:18.595 --> 00:46:19.798 AKA auto transplant,
NOTE Confidence: 0.816422500000001
00:46:19.800 --> 00:46:21.805 and then this is subsequently
NOTE Confidence: 0.816422500000001
00:46:21.805 --> 00:46:23.409 followed by maintenance therapy,
NOTE Confidence: 0.816422500000001
00:46:23.410 --> 00:46:25.816 which is usually long term and
NOTE Confidence: 0.816422500000001
00:46:25.816 --> 00:46:27.420 mental progression of disease.
NOTE Confidence: 0.816422500000001
00:46:27.420 --> 00:46:28.156 So the.
NOTE Confidence: 0.816422500000001

00:46:28.156 --> 00:46:29.628 Treatment pattern resembles a
NOTE Confidence: 0.816422500000001

00:46:29.628 --> 00:46:31.580 marathon rather than the Sprint.
NOTE Confidence: 0.816422500000001

00:46:31.580 --> 00:46:34.128 As we continue maintenance for many years.
NOTE Confidence: 0.816422500000001

00:46:34.130 --> 00:46:35.955 For those patients who remain
NOTE Confidence: 0.816422500000001

00:46:35.955 --> 00:46:37.050 in remission next.
NOTE Confidence: 0.8280961

00:46:39.170 --> 00:46:41.260 And invariably, sooner or later,
NOTE Confidence: 0.8280961

00:46:41.260 --> 00:46:43.340 every patient experiences their relapse,
NOTE Confidence: 0.8280961

00:46:43.340 --> 00:46:46.436 and this is due to branching pattern of
NOTE Confidence: 0.8280961

00:46:46.436 --> 00:46:48.399 clonal evolution or push persistence
NOTE Confidence: 0.8280961

00:46:48.399 --> 00:46:51.010 of previous clones and at the time
NOTE Confidence: 0.8280961

00:46:51.081 --> 00:46:53.937 of relapse patients have to sequence
NOTE Confidence: 0.8280961

00:46:53.937 --> 00:46:55.841 through the available therapies,
NOTE Confidence: 0.8280961

00:46:55.850 --> 00:46:58.946 each of which then leads to shorter and
NOTE Confidence: 0.8280961

00:46:58.946 --> 00:47:01.268 shorter overall duration of response,
NOTE Confidence: 0.8280961

00:47:01.270 --> 00:47:03.265 eventually leading to dismal prognosis
NOTE Confidence: 0.8280961

00:47:03.265 --> 00:47:05.860 for many of their refractory patients.

NOTE Confidence: 0.8280961

00:47:05.860 --> 00:47:08.412 Next please. Fortunately,

NOTE Confidence: 0.8280961

00:47:08.412 --> 00:47:11.304 we've had number of drug approvals

NOTE Confidence: 0.8280961

00:47:11.304 --> 00:47:14.290 over the course of the past decade,

NOTE Confidence: 0.8280961

00:47:14.290 --> 00:47:16.150 which includes the novel proteasome

NOTE Confidence: 0.8280961

00:47:16.150 --> 00:47:18.717 inhibitors in the form of carfilzomib

NOTE Confidence: 0.8280961

00:47:18.717 --> 00:47:20.640 novel immunomodulatory agents,

NOTE Confidence: 0.8280961

00:47:20.640 --> 00:47:22.002 pomalidomide, and others.

NOTE Confidence: 0.8280961

00:47:22.002 --> 00:47:24.726 The biggest breakthroughs came in 2015,

NOTE Confidence: 0.8280961

00:47:24.730 --> 00:47:27.000 when we had several approvals,

NOTE Confidence: 0.8280961

00:47:27.000 --> 00:47:29.718 namely IgG monoclonal antibody targeting CD,

NOTE Confidence: 0.8280961

00:47:29.720 --> 00:47:32.898 38 receptor on the plasma cell daratumumab,

NOTE Confidence: 0.8280961

00:47:32.900 --> 00:47:35.170 as well as checkpoint inhibitor,

NOTE Confidence: 0.8280961

00:47:35.170 --> 00:47:37.990 targeting SLAM F7 or CS1 elotuzumab.

NOTE Confidence: 0.8280961

00:47:37.990 --> 00:47:39.834 Orally available Proteus inhibitor

NOTE Confidence: 0.8280961

00:47:39.834 --> 00:47:40.756 exacum Abe.

NOTE Confidence: 0.8280961

00:47:40.760 --> 00:47:43.706 We also had approval for histone
NOTE Confidence: 0.8280961

00:47:43.706 --> 00:47:45.179 deacetylase inhibitor PANOBINOSTAT
NOTE Confidence: 0.8280961

00:47:45.179 --> 00:47:47.719 which is orally available and more
NOTE Confidence: 0.8280961

00:47:47.719 --> 00:47:50.260 recently a drugs of completely different
NOTE Confidence: 0.8280961

00:47:50.260 --> 00:47:52.680 mechanism affection such as selinexor
NOTE Confidence: 0.8280961

00:47:52.680 --> 00:47:55.590 received approval by FDA in 2019.
NOTE Confidence: 0.8280961

00:47:55.590 --> 00:47:58.500 This is a selective nuclear export
NOTE Confidence: 0.8280961

00:47:58.500 --> 00:48:00.828 inhibitor promoting some of the
NOTE Confidence: 0.8280961

00:48:00.828 --> 00:48:02.948 tumor suppressor gene action and
NOTE Confidence: 0.8280961

00:48:02.948 --> 00:48:05.955 within the past year approval of
NOTE Confidence: 0.8280961

00:48:05.955 --> 00:48:08.035 another IgG monoclonal antibody.
NOTE Confidence: 0.8280961

00:48:08.040 --> 00:48:10.929 Against CD 38 is I took some up with
NOTE Confidence: 0.8280961

00:48:10.929 --> 00:48:13.467 slightly different mechanism of action,
NOTE Confidence: 0.8280961

00:48:13.470 --> 00:48:15.930 but very similar to daratumumab and
NOTE Confidence: 0.8280961

00:48:15.930 --> 00:48:18.518 more recently just summer of last year.
NOTE Confidence: 0.8280961

00:48:18.520 --> 00:48:20.068 First antibody drug conjugate

NOTE Confidence: 0.8280961

00:48:20.068 --> 00:48:21.229 got FDA approval.

NOTE Confidence: 0.8280961

00:48:21.230 --> 00:48:23.534 This is Bill on time Out method Odin

NOTE Confidence: 0.8280961

00:48:23.534 --> 00:48:25.530 targeting B cell maturation antigen

NOTE Confidence: 0.8280961

00:48:25.530 --> 00:48:27.785 which is currently approved for

NOTE Confidence: 0.8280961

00:48:27.785 --> 00:48:29.770 relapsed refractory multiple myeloma.

NOTE Confidence: 0.8280961

00:48:29.770 --> 00:48:34.439 Beyond four prior lines of therapy next.

NOTE Confidence: 0.8280961

00:48:34.440 --> 00:48:36.350 So despite these therapeutic advances,

NOTE Confidence: 0.8280961

00:48:36.350 --> 00:48:37.954 number of clinical challenges

NOTE Confidence: 0.8280961

00:48:37.954 --> 00:48:39.959 remain primarily the concerns about

NOTE Confidence: 0.8280961

00:48:39.959 --> 00:48:42.078 what to do for refractory myeloma.

NOTE Confidence: 0.8280961

00:48:42.080 --> 00:48:43.608 Are we able to,

NOTE Confidence: 0.8280961

00:48:43.608 --> 00:48:45.518 in the novel immunotherapy era,

NOTE Confidence: 0.8280961

00:48:45.520 --> 00:48:47.698 replaced the high dose melphalan by

NOTE Confidence: 0.8280961

00:48:47.698 --> 00:48:50.403 some of the novel strategies such as

NOTE Confidence: 0.8280961

00:48:50.403 --> 00:48:52.773 car T cell or other therapeutics?

NOTE Confidence: 0.8280961

00:48:52.780 --> 00:48:55.138 How best to continue the maintenance

NOTE Confidence: 0.8280961

00:48:55.138 --> 00:48:56.710 therapy for patients particularly

NOTE Confidence: 0.8280961

00:48:56.769 --> 00:48:58.509 high risk data genetic subsets?

NOTE Confidence: 0.8280961

00:48:58.510 --> 00:49:00.880 And we're far from understanding the

NOTE Confidence: 0.8280961

00:49:00.880 --> 00:49:02.882 disease biology and choosing this

NOTE Confidence: 0.8280961

00:49:02.882 --> 00:49:05.030 sequential therapy based on biology of

NOTE Confidence: 0.8280961

00:49:05.030 --> 00:49:07.448 disease and its selection of therapy.

NOTE Confidence: 0.8280961

00:49:07.450 --> 00:49:09.774 Any cases is random and this is

NOTE Confidence: 0.8280961

00:49:09.774 --> 00:49:10.770 a clinical challenge.

NOTE Confidence: 0.8280961

00:49:10.770 --> 00:49:12.756 Same is true for a llama.

NOTE Confidence: 0.8280961

00:49:12.760 --> 00:49:13.424 Lodosa is,

NOTE Confidence: 0.8280961

00:49:13.424 --> 00:49:14.420 as you know,

NOTE Confidence: 0.8280961

00:49:14.420 --> 00:49:16.150 about 10% of multiple myeloma

NOTE Confidence: 0.8280961

00:49:16.150 --> 00:49:17.534 patients will develop concurrent

NOTE Confidence: 0.8280961

00:49:17.534 --> 00:49:19.487 soft tissue deposition of the Lambda

NOTE Confidence: 0.8280961

00:49:19.487 --> 00:49:20.727 or Kappa light chains,

NOTE Confidence: 0.8280961

00:49:20.730 --> 00:49:23.439 and this is an unmet need in all of

NOTE Confidence: 0.8280961

00:49:23.439 --> 00:49:25.380 gammopathy world as these patients,

NOTE Confidence: 0.8280961

00:49:25.380 --> 00:49:27.366 the care is not well defined,

NOTE Confidence: 0.8280961

00:49:27.370 --> 00:49:29.302 so it remains to be established

NOTE Confidence: 0.8280961

00:49:29.302 --> 00:49:31.349 what is the optimal first line,

NOTE Confidence: 0.8280961

00:49:31.350 --> 00:49:33.276 second line and beyond therapy for

NOTE Confidence: 0.8280961

00:49:33.276 --> 00:49:35.010 patients with this next please.

NOTE Confidence: 0.8280961

00:49:35.010 --> 00:49:36.775 So while facing these challenging

NOTE Confidence: 0.8280961

00:49:36.775 --> 00:49:38.780 issues in clinic we tried to.

NOTE Confidence: 0.8280961

00:49:38.780 --> 00:49:40.488 Integrate our clinical expertise

NOTE Confidence: 0.8280961

00:49:40.488 --> 00:49:43.050 and incorporate some of the Noble

NOTE Confidence: 0.8280961

00:49:43.117 --> 00:49:44.953 research therapeutic strategies and

NOTE Confidence: 0.8280961

00:49:44.953 --> 00:49:47.248 continue to educate our patients

NOTE Confidence: 0.8280961

00:49:47.248 --> 00:49:49.457 as well as our trainees next.

NOTE Confidence: 0.85143805

00:49:51.560 --> 00:49:53.840 In terms of individual focus of

NOTE Confidence: 0.85143805

00:49:53.840 --> 00:49:55.797 clinical expertise, Terry Parker has
NOTE Confidence: 0.85143805

00:49:55.797 --> 00:49:57.792 an outstanding clinical expertise in
NOTE Confidence: 0.85143805

00:49:57.792 --> 00:50:00.426 a llama low doses having served as.
NOTE Confidence: 0.85143805

00:50:00.430 --> 00:50:03.558 National Pi and number of a alloy doses,
NOTE Confidence: 0.85143805

00:50:03.560 --> 00:50:05.515 trials as well As for
NOTE Confidence: 0.85143805

00:50:05.515 --> 00:50:06.688 relapsed refractory myeloma.
NOTE Confidence: 0.85143805

00:50:06.690 --> 00:50:08.645 Nofar nofar sparkles has been
NOTE Confidence: 0.85143805

00:50:08.645 --> 00:50:10.600 mostly on high dose melphalan.
NOTE Confidence: 0.85143805

00:50:10.600 --> 00:50:12.856 Autologous stem cell transplant for myeloma
NOTE Confidence: 0.85143805

00:50:12.856 --> 00:50:15.679 as well as cellular therapies in myeloma.
NOTE Confidence: 0.85143805

00:50:15.680 --> 00:50:17.744 Sabrina also has an excellent expertise
NOTE Confidence: 0.85143805

00:50:17.744 --> 00:50:20.405 in a llama low doses shoot the
NOTE Confidence: 0.85143805

00:50:20.405 --> 00:50:22.033 separate fellowship in amyloidosis
NOTE Confidence: 0.85143805

00:50:22.033 --> 00:50:24.280 at the Boston Medical Center.
NOTE Confidence: 0.85143805

00:50:24.280 --> 00:50:26.285 She also focuses on understanding
NOTE Confidence: 0.85143805

00:50:26.285 --> 00:50:28.748 the biology of some of the

NOTE Confidence: 0.85143805

00:50:28.748 --> 00:50:30.658 precursor States and my own.

NOTE Confidence: 0.85143805

00:50:30.660 --> 00:50:33.205 Clinical research has focused On's

NOTE Confidence: 0.85143805

00:50:33.205 --> 00:50:35.241 to understanding clonal heterogeneity

NOTE Confidence: 0.85143805

00:50:35.241 --> 00:50:38.164 and incorporating advanced imaging in

NOTE Confidence: 0.85143805

00:50:38.164 --> 00:50:40.508 this disease therapeutic assessment.

NOTE Confidence: 0.85143805

00:50:40.510 --> 00:50:43.107 So education is of course an integral

NOTE Confidence: 0.85143805

00:50:43.107 --> 00:50:45.049 component of our daily work.

NOTE Confidence: 0.85143805

00:50:45.050 --> 00:50:47.535 This is a group of current fellows

NOTE Confidence: 0.85143805

00:50:47.535 --> 00:50:49.079 rotating through myeloma clinics

NOTE Confidence: 0.85143805

00:50:49.079 --> 00:50:50.719 during this academic year,

NOTE Confidence: 0.85143805

00:50:50.720 --> 00:50:53.331 and many of them have been involved

NOTE Confidence: 0.85143805

00:50:53.331 --> 00:50:55.249 in research projects in myeloma.

NOTE Confidence: 0.85143805

00:50:55.250 --> 00:50:56.294 So, for instance,

NOTE Confidence: 0.85143805

00:50:56.294 --> 00:50:58.382 Weixin Lou has been working on

NOTE Confidence: 0.85143805

00:50:58.382 --> 00:51:00.168 myeloma Yale Database project.

NOTE Confidence: 0.85143805

00:51:00.170 --> 00:51:02.438 On looking at outcomes in patients
NOTE Confidence: 0.85143805

00:51:02.438 --> 00:51:03.950 treated with monoclonal antibodies,
NOTE Confidence: 0.85143805

00:51:03.950 --> 00:51:06.197 Talib Dasani has the bone disease in
NOTE Confidence: 0.85143805

00:51:06.197 --> 00:51:08.593 myeloma cohort and looking to develop
NOTE Confidence: 0.85143805

00:51:08.593 --> 00:51:10.425 quality improvement project started.
NOTE Confidence: 0.85143805

00:51:10.430 --> 00:51:12.902 Targeting this Eric Chang will be
NOTE Confidence: 0.85143805

00:51:12.902 --> 00:51:15.050 involved in this promise study,
NOTE Confidence: 0.85143805

00:51:15.050 --> 00:51:17.444 which is the screening and community
NOTE Confidence: 0.85143805

00:51:17.444 --> 00:51:19.557 outreach project for patients with
NOTE Confidence: 0.85143805

00:51:19.557 --> 00:51:21.349 gammopathy's and their families,
NOTE Confidence: 0.85143805

00:51:21.350 --> 00:51:24.290 and it has an important outreach project,
NOTE Confidence: 0.85143805

00:51:24.290 --> 00:51:26.702 and we're partnering with Dana Farber
NOTE Confidence: 0.85143805

00:51:26.702 --> 00:51:28.910 Doctor Ghobrial on this project.
NOTE Confidence: 0.85143805

00:51:28.910 --> 00:51:29.742 And finally,
NOTE Confidence: 0.85143805

00:51:29.742 --> 00:51:32.238 Rose Mirkin will be involved in
NOTE Confidence: 0.85143805

00:51:32.238 --> 00:51:34.371 the collaborative effort where we

NOTE Confidence: 0.85143805

00:51:34.371 --> 00:51:36.825 may study the antigenic targets of

NOTE Confidence: 0.85143805

00:51:36.825 --> 00:51:38.570 monoclonal antibodies of myeloma

NOTE Confidence: 0.85143805

00:51:38.570 --> 00:51:41.630 with the help of immunology. Lab of.

NOTE Confidence: 0.85143805

00:51:41.630 --> 00:51:43.550 Aaron rink next please.

NOTE Confidence: 0.8216927

00:51:45.600 --> 00:51:47.164 So our research consists

NOTE Confidence: 0.8216927

00:51:47.164 --> 00:51:48.337 of different missions.

NOTE Confidence: 0.8216927

00:51:48.340 --> 00:51:51.148 On one hand, we always try to enhance

NOTE Confidence: 0.8216927

00:51:51.148 --> 00:51:53.049 our clinical trial portfolio.

NOTE Confidence: 0.8216927

00:51:53.050 --> 00:51:54.462 We have ongoing trials,

NOTE Confidence: 0.8216927

00:51:54.462 --> 00:51:56.580 both investigator initiated as well as

NOTE Confidence: 0.8216927

00:51:56.647 --> 00:51:58.927 industry and collaborative group trials.

NOTE Confidence: 0.8216927

00:51:58.930 --> 00:52:01.276 In every space of this disease,

NOTE Confidence: 0.8216927

00:52:01.280 --> 00:52:02.363 including early stage,

NOTE Confidence: 0.8216927

00:52:02.363 --> 00:52:04.890 small during as well as newly diagnosed

NOTE Confidence: 0.8216927

00:52:04.948 --> 00:52:07.158 and late relapsed refractory patients.

NOTE Confidence: 0.8216927

00:52:07.160 --> 00:52:09.666 And we always try to develop additional
NOTE Confidence: 0.8216927

00:52:09.666 --> 00:52:11.859 therapeutic concepts for refractory myeloma.
NOTE Confidence: 0.8216927

00:52:11.860 --> 00:52:13.471 Andale Emily doses.
NOTE Confidence: 0.8216927

00:52:13.471 --> 00:52:15.619 On the other hand,
NOTE Confidence: 0.8216927

00:52:15.620 --> 00:52:17.770 we do have certain outcomes,
NOTE Confidence: 0.8216927

00:52:17.770 --> 00:52:19.550 research initiatives and this
NOTE Confidence: 0.8216927

00:52:19.550 --> 00:52:22.698 include both myeloma as well as Mgas
NOTE Confidence: 0.8216927

00:52:22.698 --> 00:52:25.074 database as well as bone disease.
NOTE Confidence: 0.8216927

00:52:25.080 --> 00:52:27.080 In myeloma collaboration with our
NOTE Confidence: 0.8216927

00:52:27.080 --> 00:52:29.622 copper team and finally on the
NOTE Confidence: 0.8216927

00:52:29.622 --> 00:52:31.957 research basic Science Research front,
NOTE Confidence: 0.8216927

00:52:31.960 --> 00:52:34.366 we've been trying to build teams
NOTE Confidence: 0.8216927

00:52:34.366 --> 00:52:35.970 to collaborate with researchers
NOTE Confidence: 0.8216927

00:52:36.036 --> 00:52:37.980 to study monoclonal antibodies.
NOTE Confidence: 0.8216927

00:52:37.980 --> 00:52:40.170 They're driving antigens and Additionally
NOTE Confidence: 0.8216927

00:52:40.170 --> 00:52:42.360 mean profiling to understand predictive

NOTE Confidence: 0.8216927

00:52:42.421 --> 00:52:44.097 biomarkers of disease response.

NOTE Confidence: 0.8216927

00:52:44.100 --> 00:52:48.726 And study extramedullary disease next please.

NOTE Confidence: 0.8216927

00:52:48.730 --> 00:52:51.474 So on the basic science research front,

NOTE Confidence: 0.8216927

00:52:51.480 --> 00:52:53.244 I think the.

NOTE Confidence: 0.8216927

00:52:53.244 --> 00:52:54.420 Stephanie Collins,

NOTE Confidence: 0.8216927

00:52:54.420 --> 00:52:56.545 Biobank project for hematology has

NOTE Confidence: 0.8216927

00:52:56.545 --> 00:52:59.162 been really instrumental in our program

NOTE Confidence: 0.8216927

00:52:59.162 --> 00:53:01.257 at North Haven Myeloma program.

NOTE Confidence: 0.8216927

00:53:01.260 --> 00:53:03.325 We've essentially biobank the bone

NOTE Confidence: 0.8216927

00:53:03.325 --> 00:53:05.854 marrow and peripheral blood on every

NOTE Confidence: 0.8216927

00:53:05.854 --> 00:53:07.854 single patient that we diagnosed

NOTE Confidence: 0.8216927

00:53:07.854 --> 00:53:10.220 with multiple myeloma or gammopathy,

NOTE Confidence: 0.8216927

00:53:10.220 --> 00:53:12.500 and we hope to build collaboration

NOTE Confidence: 0.8216927

00:53:12.500 --> 00:53:15.736 and with the help from David Shatz lab

NOTE Confidence: 0.8216927

00:53:15.736 --> 00:53:18.190 to develop ex vivo multiple myeloma

NOTE Confidence: 0.8216927

00:53:18.272 --> 00:53:21.122 mouse models where we can develop

NOTE Confidence: 0.8216927

00:53:21.122 --> 00:53:23.573 robust preclinical models using this.

NOTE Confidence: 0.8216927

00:53:23.573 --> 00:53:24.659 In addition,

NOTE Confidence: 0.8216927

00:53:24.659 --> 00:53:26.288 studying monoclonal antibodies

NOTE Confidence: 0.8216927

00:53:26.288 --> 00:53:28.460 and understanding the antigenic

NOTE Confidence: 0.8216927

00:53:28.528 --> 00:53:31.060 targets and what drives the disease

NOTE Confidence: 0.8216927

00:53:31.060 --> 00:53:33.232 in collaboration with Aaron Rings

NOTE Confidence: 0.8216927

00:53:33.232 --> 00:53:35.297 lab on clinical research front,

NOTE Confidence: 0.8216927

00:53:35.300 --> 00:53:37.808 we've had active clinical

NOTE Confidence: 0.8216927

00:53:37.808 --> 00:53:40.943 collaboration and couple of IIT's.

NOTE Confidence: 0.8216927

00:53:40.950 --> 00:53:42.666 Closely working with musculoskeletal

NOTE Confidence: 0.8216927

00:53:42.666 --> 00:53:44.811 radiology and in this and

NOTE Confidence: 0.8216927

00:53:44.811 --> 00:53:46.229 haimson ending lishouk,

NOTE Confidence: 0.8216927

00:53:46.230 --> 00:53:48.430 both have been instrumental as

NOTE Confidence: 0.8216927

00:53:48.430 --> 00:53:50.630 well as our pathology colleagues.

NOTE Confidence: 0.8216927

00:53:50.630 --> 00:53:53.710 Mean issue and sang and pen know.

NOTE Confidence: 0.8216927

00:53:53.710 --> 00:53:55.370 Farhan Sabrina have ongoing

NOTE Confidence: 0.8216927

00:53:55.370 --> 00:53:57.445 collaboration with an Habermann from

NOTE Confidence: 0.8216927

00:53:57.445 --> 00:53:59.783 lab laboratory medicine to understand

NOTE Confidence: 0.8216927

00:53:59.783 --> 00:54:02.103 immune profiling of patients to

NOTE Confidence: 0.8216927

00:54:02.103 --> 00:54:04.340 understand the biologic response in

NOTE Confidence: 0.8216927

00:54:04.340 --> 00:54:06.475 different subsets of myeloma patients

NOTE Confidence: 0.8216927

00:54:06.475 --> 00:54:08.230 treated with monoclonal antibodies

NOTE Confidence: 0.8216927

00:54:08.230 --> 00:54:10.430 in terms of outcomes research.

NOTE Confidence: 0.8216927

00:54:10.430 --> 00:54:12.242 We've had active collaboration

NOTE Confidence: 0.8216927

00:54:12.242 --> 00:54:14.054 with hematology copper team.

NOTE Confidence: 0.8216927

00:54:14.060 --> 00:54:16.060 With the leadership of Shammai,

NOTE Confidence: 0.8216927

00:54:16.060 --> 00:54:17.660 my and Scott Huntington,

NOTE Confidence: 0.8216927

00:54:17.660 --> 00:54:19.660 we have several ongoing projects,

NOTE Confidence: 0.8216927

00:54:19.660 --> 00:54:22.084 and one of them a recent one using

NOTE Confidence: 0.8216927

00:54:22.084 --> 00:54:24.719 flat iron database and one particular

NOTE Confidence: 0.8216927

00:54:24.719 --> 00:54:27.653 myeloma project examining patterns of care,
NOTE Confidence: 0.8216927

00:54:27.660 --> 00:54:31.258 especially in the context of kovid period.
NOTE Confidence: 0.8216927

00:54:31.260 --> 00:54:32.092 And Lastly,
NOTE Confidence: 0.8216927

00:54:32.092 --> 00:54:35.420 we've been trying to build this disease team,
NOTE Confidence: 0.8216927

00:54:35.420 --> 00:54:37.910 which we refer to myeloma bone
NOTE Confidence: 0.8216927

00:54:37.910 --> 00:54:39.155 disease program collaboration,
NOTE Confidence: 0.8216927

00:54:39.160 --> 00:54:41.656 under which we try to bring
NOTE Confidence: 0.8216927

00:54:41.656 --> 00:54:42.904 together different departments,
NOTE Confidence: 0.8216927

00:54:42.910 --> 00:54:44.550 including Endocrinology, Carlin, Sonia,
NOTE Confidence: 0.8216927

00:54:44.550 --> 00:54:47.480 as well as orthopedic and spine center,
NOTE Confidence: 0.8216927

00:54:47.480 --> 00:54:49.560 Dieter, Lindskog, and Louise called.
NOTE Confidence: 0.8216927

00:54:49.560 --> 00:54:51.048 And as I said,
NOTE Confidence: 0.8216927

00:54:51.048 --> 00:54:53.280 Talib Dosani has an ongoing outcomes
NOTE Confidence: 0.8216927

00:54:53.355 --> 00:54:56.638 project looking into bone disease in myeloma.
NOTE Confidence: 0.8216927

00:54:56.640 --> 00:54:59.130 So with that I will stop.
NOTE Confidence: 0.8216927

00:54:59.130 --> 00:55:01.788 I'm exciting to have such great

NOTE Confidence: 0.8216927

00:55:01.788 --> 00:55:04.410 collaborators and colleagues on the campus.

NOTE Confidence: 0.8216927

00:55:04.410 --> 00:55:05.922 And I will leave a couple of

NOTE Confidence: 0.8216927

00:55:05.922 --> 00:55:06.570 minutes for questions.

NOTE Confidence: 0.8216927

00:55:06.570 --> 00:55:09.318 Thank you so much.

NOTE Confidence: 0.8216927

00:55:09.320 --> 00:55:09.720 Awesome,

NOTE Confidence: 0.8470994

00:55:09.720 --> 00:55:12.108 alright, so I'll share my screen.

NOTE Confidence: 0.8470994

00:55:12.110 --> 00:55:14.095 Just people know we have

NOTE Confidence: 0.8470994

00:55:14.095 --> 00:55:15.286 hematology joins 2021.

NOTE Confidence: 0.8470994

00:55:15.290 --> 00:55:17.300 We have a Twitter handle

NOTE Confidence: 0.8470994

00:55:17.300 --> 00:55:19.670 so we'll try and use it,

NOTE Confidence: 0.8470994

00:55:19.670 --> 00:55:23.206 so I'm going to unshare so we can

NOTE Confidence: 0.8470994

00:55:23.206 --> 00:55:26.273 see everybody and let me pull up the

NOTE Confidence: 0.8470994

00:55:26.273 --> 00:55:29.640 chat to see if there are questions.

NOTE Confidence: 0.8470994

00:55:29.640 --> 00:55:32.049 Are there questions?

NOTE Confidence: 0.8470994

00:55:32.050 --> 00:55:34.240 Would anybody like to raise their

NOTE Confidence: 0.8470994

00:55:34.240 --> 00:55:36.430 hand and ask the question?
NOTE Confidence: 0.8470994

00:55:36.430 --> 00:55:39.121 If not, I can start with one and then
NOTE Confidence: 0.8470994

00:55:39.121 --> 00:55:41.483 maybe I'll ask Francine since I'm
NOTE Confidence: 0.8470994

00:55:41.483 --> 00:55:44.225 always a molecular person and I know
NOTE Confidence: 0.8470994

00:55:44.225 --> 00:55:46.271 that we have this phenomenal effort
NOTE Confidence: 0.8470994

00:55:46.271 --> 00:55:49.066 to get on this goal panel and whole
NOTE Confidence: 0.8470994

00:55:49.066 --> 00:55:50.470 exome sequencing tower patients.
NOTE Confidence: 0.8470994

00:55:50.470 --> 00:55:52.576 Do you think that that will
NOTE Confidence: 0.8470994

00:55:52.576 --> 00:55:53.629 fulfill your need?
NOTE Confidence: 0.8470994

00:55:53.630 --> 00:55:57.490 Or what do we need to do to improve on that?
NOTE Confidence: 0.886944

00:55:58.450 --> 00:56:00.118 I think that's certainly a start.
NOTE Confidence: 0.886944

00:56:00.120 --> 00:56:01.788 You know, as you know Stephanie,
NOTE Confidence: 0.886944

00:56:01.790 --> 00:56:03.930 we see some of these.
NOTE Confidence: 0.886944

00:56:03.930 --> 00:56:06.352 We are rare lymphoma patients for whom
NOTE Confidence: 0.886944

00:56:06.352 --> 00:56:08.131 there's really no treatment algorithm
NOTE Confidence: 0.886944

00:56:08.131 --> 00:56:10.843 and which is kind of picking out of

NOTE Confidence: 0.886944

00:56:10.913 --> 00:56:13.193 a hat to try to figure out what to do

NOTE Confidence: 0.886944

00:56:13.200 --> 00:56:15.048 in the error of precision medicine.

NOTE Confidence: 0.886944

00:56:15.050 --> 00:56:17.130 I really think that we should be profiling

NOTE Confidence: 0.886944

00:56:17.130 --> 00:56:18.819 these patients and sequencing them

NOTE Confidence: 0.886944

00:56:18.819 --> 00:56:20.307 and rationally developing strategies,

NOTE Confidence: 0.886944

00:56:20.310 --> 00:56:22.389 so we would love to be able

NOTE Confidence: 0.886944

00:56:22.389 --> 00:56:23.710 to start doing that.

NOTE Confidence: 0.886944

00:56:23.710 --> 00:56:26.174 I think the critical component of that is,

NOTE Confidence: 0.886944

00:56:26.180 --> 00:56:28.332 you know, is being able to get hold

NOTE Confidence: 0.886944

00:56:28.332 --> 00:56:30.499 of that issue when it's biopsied,

NOTE Confidence: 0.886944

00:56:30.500 --> 00:56:32.980 and to get it to the right place

NOTE Confidence: 0.886944

00:56:32.980 --> 00:56:34.619 as soon as possible.

NOTE Confidence: 0.886944

00:56:34.620 --> 00:56:36.790 We're also very interested in

NOTE Confidence: 0.886944

00:56:36.790 --> 00:56:38.960 looking at circulating tumor cells

NOTE Confidence: 0.886944

00:56:39.035 --> 00:56:41.153 and whether that's a strategy that

NOTE Confidence: 0.886944

00:56:41.153 --> 00:56:43.448 we could we could use as well.
NOTE Confidence: 0.886944

00:56:43.450 --> 00:56:44.030 OK
NOTE Confidence: 0.8107474

00:56:44.030 --> 00:56:45.354 fantastic exciting.
NOTE Confidence: 0.8107474

00:56:45.354 --> 00:56:48.664 Are there any other questions?
NOTE Confidence: 0.8107474

00:56:48.670 --> 00:56:51.176 I don't see any in the chat.
NOTE Confidence: 0.85690224

00:56:53.920 --> 00:56:56.958 So one of the I'm sorry Charlie friends, you
NOTE Confidence: 0.85690224

00:56:56.960 --> 00:56:59.158 know, I guess I would ask and
NOTE Confidence: 0.85690224

00:56:59.158 --> 00:57:01.692 I think you each allude to it,
NOTE Confidence: 0.85690224

00:57:01.692 --> 00:57:04.734 but where do you think cell therapy is going?
NOTE Confidence: 0.85690224

00:57:04.740 --> 00:57:06.600 And obviously it's relevant to each
NOTE Confidence: 0.85690224

00:57:06.600 --> 00:57:08.450 of the domains being described.
NOTE Confidence: 0.85690224

00:57:08.450 --> 00:57:11.213 So where do you think five years from now
NOTE Confidence: 0.85690224

00:57:11.213 --> 00:57:13.857 will be with respect to cell therapies?
NOTE Confidence: 0.80907613

00:57:14.630 --> 00:57:15.569 Well, we talk
NOTE Confidence: 0.80907613

00:57:15.570 --> 00:57:17.394 a lot about that with respect
NOTE Confidence: 0.80907613

00:57:17.394 --> 00:57:19.299 to transplant that we were just

NOTE Confidence: 0.80907613

00:57:19.299 --> 00:57:21.177 talking out at BMT rounds today.

NOTE Confidence: 0.80907613

00:57:21.180 --> 00:57:23.178 About whether we'll be doing autologous

NOTE Confidence: 0.80907613

00:57:23.178 --> 00:57:24.930 transplants in the future or not.

NOTE Confidence: 0.80907613

00:57:24.930 --> 00:57:26.835 I think that that's kind

NOTE Confidence: 0.80907613

00:57:26.835 --> 00:57:28.359 of where we're heading.

NOTE Confidence: 0.80907613

00:57:28.360 --> 00:57:30.320 I just wanted to say that one of

NOTE Confidence: 0.80907613

00:57:30.320 --> 00:57:31.958 the things that yell is doing,

NOTE Confidence: 0.80907613

00:57:31.960 --> 00:57:33.738 by the way, is we are developing

NOTE Confidence: 0.80907613

00:57:33.738 --> 00:57:35.574 our own party and we didn't get

NOTE Confidence: 0.80907613

00:57:35.574 --> 00:57:37.098 a chance to talk about that.

NOTE Confidence: 0.80907613

00:57:37.100 --> 00:57:38.355 But Doctor Katz and colleagues

NOTE Confidence: 0.80907613

00:57:38.355 --> 00:57:39.920 have developed the RNA car strategy

NOTE Confidence: 0.80907613

00:57:39.920 --> 00:57:41.205 and we're working on that.

NOTE Confidence: 0.80907613

00:57:41.210 --> 00:57:42.978 I know he has a B cell construct

NOTE Confidence: 0.80907613

00:57:42.978 --> 00:57:44.809 as well as one vertice Oklahoma,

NOTE Confidence: 0.80907613

00:57:44.810 --> 00:57:46.658 so I think the whole car world
NOTE Confidence: 0.80907613

00:57:46.658 --> 00:57:47.889 is undergoing evolution as well.
NOTE Confidence: 0.80907613

00:57:47.890 --> 00:57:49.462 And hopefully we're going to be
NOTE Confidence: 0.80907613

00:57:49.462 --> 00:57:51.228 at the forefront of some of that.
NOTE Confidence: 0.80169636

00:57:55.280 --> 00:57:58.065 Don't there's a question from the
NOTE Confidence: 0.80169636

00:57:58.065 --> 00:58:00.420 audience will then from Doctor
NOTE Confidence: 0.80169636

00:58:00.502 --> 00:58:03.364 Chi with a new drug substitute
NOTE Confidence: 0.80169636

00:58:03.364 --> 00:58:05.786 of chemotherapy. In treatments.
NOTE Confidence: 0.80169636

00:58:05.786 --> 00:58:10.184 Also, with the new drug substitute
NOTE Confidence: 0.80169636

00:58:10.184 --> 00:58:12.640 chemotherapy treatment. From Doctor chi.
NOTE Confidence: 0.83162725

00:58:18.140 --> 00:58:20.006 Yeah, I mean, I think that's
NOTE Confidence: 0.83162725

00:58:20.006 --> 00:58:21.250 a question to everybody.
NOTE Confidence: 0.83162725

00:58:21.250 --> 00:58:23.116 Can we get rid of chemo?
NOTE Confidence: 0.83162725

00:58:23.120 --> 00:58:24.050 This toxic stuff?
NOTE Confidence: 0.7844128

00:58:26.360 --> 00:58:29.622 We are that we added Temple where
NOTE Confidence: 0.7844128

00:58:29.622 --> 00:58:32.549 we were able to to do that,

NOTE Confidence: 0.7844128

00:58:32.550 --> 00:58:34.760 like I acute firestick leukemias.

NOTE Confidence: 0.7844128

00:58:34.760 --> 00:58:38.734 I mean, that's that's a poster child, I know.

NOTE Confidence: 0.7844128

00:58:38.734 --> 00:58:41.329 But potentially yes, that can be.

NOTE Confidence: 0.7844128

00:58:41.329 --> 00:58:45.810 That can be the one of the goal we have.

NOTE Confidence: 0.7844128

00:58:45.810 --> 00:58:48.336 We should not basically forget that

NOTE Confidence: 0.7844128

00:58:48.336 --> 00:58:50.670 chemotherapy is AB side effects,

NOTE Confidence: 0.7844128

00:58:50.670 --> 00:58:53.757 but targeted therapies have side effects too,

NOTE Confidence: 0.7844128

00:58:53.760 --> 00:58:56.350 and so we should not.

NOTE Confidence: 0.7844128

00:58:56.350 --> 00:58:58.540 Situation where we are really,

NOTE Confidence: 0.7844128

00:58:58.540 --> 00:58:59.430 completely disparaging.

NOTE Confidence: 0.7844128

00:58:59.430 --> 00:59:02.990 Chemo too much as it's as some real

NOTE Confidence: 0.7844128

00:59:03.075 --> 00:59:05.523 basically benefits for for some of

NOTE Confidence: 0.7844128

00:59:05.523 --> 00:59:07.673 the patient and for chemotherapy

NOTE Confidence: 0.7844128

00:59:07.673 --> 00:59:10.325 as well As for cell therapy.

NOTE Confidence: 0.7844128

00:59:10.330 --> 00:59:13.903 I think we need to see the big picture

NOTE Confidence: 0.7844128

00:59:13.903 --> 00:59:17.850 and how we can sequence and combine
NOTE Confidence: 0.7844128

00:59:17.850 --> 00:59:21.200 these different modalities of treatment.
NOTE Confidence: 0.7844128

00:59:21.200 --> 00:59:22.675 Rather than being one again
NOTE Confidence: 0.7844128

00:59:22.675 --> 00:59:23.855 the again the other.
NOTE Confidence: 0.85236925

00:59:26.420 --> 00:59:28.514 Awesome, so I think we have
NOTE Confidence: 0.85236925

00:59:28.514 --> 00:59:30.845 reached 1:00 o'clock or one minute
NOTE Confidence: 0.85236925

00:59:30.845 --> 00:59:32.577 past 1:00 o'clock tomorrow.
NOTE Confidence: 0.85236925

00:59:32.580 --> 00:59:34.890 Francine Natalia thank you for the
NOTE Confidence: 0.85236925

00:59:34.890 --> 00:59:35.990 fantastic presentation, Charlie.
NOTE Confidence: 0.85236925

00:59:35.990 --> 00:59:37.970 Thank you for hosting us and
NOTE Confidence: 0.85236925

00:59:37.970 --> 00:59:40.394 thank you for everything on behalf
NOTE Confidence: 0.85236925

00:59:40.394 --> 00:59:42.210 of everybody in immortality.
NOTE Confidence: 0.85236925

00:59:42.210 --> 00:59:44.898 And thank you to everybody who's attending.
NOTE Confidence: 0.85236925

00:59:44.900 --> 00:59:46.830 Yeah, phenomenal work. I just
NOTE Confidence: 0.85236925

00:59:46.830 --> 00:59:48.858 think about in my tenure what's
NOTE Confidence: 0.85236925

00:59:48.858 --> 00:59:51.060 been going on in hematology.

NOTE Confidence: 0.85236925

00:59:51.060 --> 00:59:53.056 Yeah, it's really exciting.

NOTE Confidence: 0.85236925

00:59:53.056 --> 00:59:55.551 So congratulations to all the

NOTE Confidence: 0.85236925

00:59:55.551 --> 00:59:57.881 speakers and all the investigators

NOTE Confidence: 0.85236925

00:59:57.881 --> 01:00:02.411 and staff working on this. No. OK.